Company name,Generic name,Brand name,FDA approval status,Approval date,Drug class,Target(s),Mechanism of action,Indications,Current clinical trials
Roche/Genentech,ATEZOLIZUMAB,Tecentriq,Y,2025-08-22,Monoclonal Antibody,PD-L1,Monoclonal Antibody,adult patients with metastatic NSCLC who have disease | adult patients with metastatic NSCLC who have disease | adult patients with unresectable or metastatic hepatocellular carcinoma | adult patients with unresectable or metastatic hepatocellular carcinoma | adult patients with unresectable or metastatic hepatocellular carcinoma | positive unresectable or metastatic melanoma | positive unresectable or metastatic melanoma | years of age and older with unresectable or metastatic alveolar soft part sarcoma | years of age and older with unresectable or metastatic alveolar soft part sarcoma | adult patients with metastatic NSCLC whose tumor | of tumor | stained tumor | of the tumor | with no EGFR or ALK genomic tumor | squamous NSCLC with no EGFR or ALK genomic tumor | stage small cell lung cancer | stage small cell lung cancer | stage small cell lung cancer | stage small cell lung cancer | stage small cell lung cancer | adult patients with metastatic non-small cell | IIIA NSCLC who had complete tumor | line treatment of adult patients with metastatic non-small cell | line treatment of adult patients with metastatic non-small cell | the treatment of adult patients with metastatic NSCLC who have disease | the treatment of adult patients with metastatic NSCLC who have disease | the treatment of adult patients with unresectable or metastatic hepatocellular carcinoma | the treatment of adult patients with unresectable or metastatic hepatocellular carcinoma | the treatment of adult patients with unresectable or metastatic hepatocellular carcinoma | for the treatment of adult patients with metastatic NSCLC who have disease | for the treatment of adult patients with metastatic NSCLC who have disease | for the treatment of adult patients with unresectable or metastatic hepatocellular carcinoma | for the treatment of adult patients with unresectable or metastatic hepatocellular carcinoma | for the treatment of adult patients with unresectable or metastatic hepatocellular carcinoma | adult patients with unresectable or metastatic alveolar soft part sarcoma | the treatment of adult patients with unresectable or metastatic alveolar soft part sarcoma | for the treatment of adult patients with unresectable or metastatic alveolar soft part sarcoma,"A Two-Arm Randomized, Double-Blind, Placebo-Controlled Phase 2 Selection Trial to Evaluate the Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With HPV16-Positive, PD-L1-positive, Recurrent or Metastatic Cervical Cancer Who Are Refractory to Pembrolizumab With Chemotherapy With/Without Bevacizumab. | Phase 2 | Withdrawn | NCT06099418 || A Phase II Single-arm, Open-label Study of Atezolizumab and Derazantinib for Patients With Advanced Intrahepatic Cholangiocarcinoma With FGFR2 | Unknown | Recruiting | NCT05174650 || A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Patients With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma | Unknown | Recruiting | NCT04540211 || A Phase II, Open Label, Randomized, Non-Comparative Cohorts Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors with Resectable Disease with Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H) | Unknown | Withdrawn | NCT06331598 || Phase 2 Trial of TGF-β2 Inhibition (OT-101) With Atezolizumab as Second-Line or Third-Line Therapy for Patients Previously Treated With Immunotherapy (+/- Chemotherapy) With Metastatic Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Withdrawn | NCT05935774 || An Open-Label, Multicenter, Randomized, Dose-Escalation and Extension, Phase IA/IB Study to Evaluate Safety and Anti-Tumor Activity of RO7284755, A PD-1 Targeted IL-2 Variant (IL-2V) Immunocytokine, Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors | Unknown | Recruiting | NCT04303858 || A Phase 2/3 Randomized, Open Label, Multicenter Study to Evaluate the Optimal Dose, Safety, and Efficacy of ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Subjects With Previously Untreated Extensive Stage Small Cell Lung Cancer (ES-SCLC) | Phase 2 | Recruiting | NCT07155174 || A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination With Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects With Metastatic Castration-Resistant Prostate Cancer | Unknown | Recruiting | NCT04446117 || Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA) | Unknown | Recruiting | NCT05690048 || A Multinational, Double-blind, Placebo-Controlled, Parallel Randomized Arms, Phase II Trial to Compare Safety and Efficacy of Selective Internal Radiation Therapy (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab) Versus Selective Internal Radiation Therapy (SIRT-Y90) Followed by Placebo in Patients With Locally Advanced Hepatocellular Carcinoma (HCC) | Unknown | Recruiting | NCT05377034 || A Prospective, Multicenter Phase II Clinical Study of Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIB Driver Gene-negative Non-small Cell Lung Cancer (NSCLC) | Unknown | Recruiting | NCT05295212 || An Open-Label, Multicenter Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C) | Unknown | Recruiting | NCT05112965 || Randomized Phase II Trial Evaluating the Efficacy of Paclitaxel+Bevacizumab INDUCtion Followed by at atEzolizumab+Nab-paclitaxel for PD-L1-positive Metastatic Triple Negative Breast Cancer (JBCRG-M10, CMA-0196) (INDUCE Trial) | Unknown | Recruiting | NCT06793553 || Phase 1/2 Open Label, Safety and Preliminary Efficacy Study of a Live Biotherapeutic Product (CJRB-101) in Combination With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer | Phase 1 | Recruiting | NCT05877430 || A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Patients With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy | Unknown | Terminated | NCT03029832 || The Impact of HER2 Heterogeneity on the Treatment of Early-stage HER2-positive Breast Cancer: a Phase II Study of T-DM1 in Combination With Pertuzumab in the Preoperative Setting | Unknown | Recruiting | NCT02326974 || A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Patients With Resected Pancreatic Ductal Adenocarcinoma | Unknown | Recruiting | NCT05968326 || Neoadjuvant Treatment With the Combination of Vemurafenib, Cobimetinib and Atezolizumab in Limited Metastasis of Malignant Melanoma (AJCC Stage IIIC/IV) and Integrated Biomarker Study: a Single Armed, Two Cohort, Phase II EADO Trial NEO-VC | Unknown | Terminated | NCT02303951 || A Phase 2 Study of Atezolizumab and Cobimetinib in PD-1/PD-L1 Inhibitor Resistant or Refractory Non-Small Cell Lung Cancer | Phase 2 | Recruiting | NCT03600701 || Phase II Study of BEvacizumab (Avastin) in Combination With Atezolizumab or Atezolizumab (Tencentriq) and Cobimetinib (Cotellic) in Patients With Untreated Melanoma Brain Metastases (TACo-BEAT-MBM) | Unknown | Recruiting | NCT03175432 || Phase II Trial of Atezolizumab and Tiragolumab for Patients With Detectable Circulating Tumor DNA After Definitive Treatment for HPV-positive Squamous Cell Carcinoma | Unknown | Withdrawn | NCT06762808 || A Phase II Randomized Study of Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection | Unknown | Terminated | NCT05060003 || A Phase Ia/Ib Open-Label, Multicenter Study Evaluating the Safety and Pharmacokinetics of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma, and as a Single Agent and in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | Unknown | Terminated | NCT04045028 || A Phase II Clinical Trial of Tiragolumab in Combination With Atezolizumab in Patients With Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases. | Unknown | Recruiting | NCT05746481 || A Phase III, Randomized, Double-Blinded, Placebo-Controlled Study of Tiragolumab, an Anti-Tigit Antibody, in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer | Unknown | Recruiting | NCT04294810 || Phase 2 and Biomarker Trial of Anti-TIGIT and Anti-PDL1 in Patients With Recurrent Glioblastoma | Phase 2 | Withdrawn | NCT06328036 || A Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Patients With Previously Untreated Advanced Non-Squamous Non-Small-Cell Lung Cancer | Unknown | Recruiting | NCT04619797 || A Phase II Trial of Tiragolumab in Combination With Atezolizumab and Bevacizumab in Patients With Previously Treated, Microsatellite Stable, Metastatic Colorectal Adenocarcinoma | Unknown | Recruiting | NCT06784947 || An Open-label, Multi-centric, Phase I, Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT) | Unknown | Recruiting | NCT05259319 || A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer | Unknown | Recruiting | NCT04665856 || A Phase II, Randomized, Open Label, Parallel-group Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer | Unknown | Recruiting | NCT05009069 || A Phase 1b/2, Multicenter, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody-Drug Conjugate (ADC), in Combination With Atezolizumab With or Without Carboplatin as First-line Induction or Maintenance, in Subjects With Extensive-stage Small Cell Lung Cancer (ES-SCLC) (IDeate-Lung03) | Phase 1 | Recruiting | NCT06362252 || A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN328 Monotherapy and HPN328 With Atezolizumab or Ifinatamab Deruxtecan (I-DXd) in Patients With Advanced Cancers Associated With Expression of Delta-like Canonical Notch Ligand 3 (DLL3). | Phase 1 | Recruiting | NCT04471727"
Roche/Genentech,INAVOLISIB,Itovebi,Y,2025-01-22,Kinase Inhibitor,PI3K,Kinase Inhibitor,locally advanced or metastatic breast cancer | locally advanced or metastatic breast cancer | locally advanced or metastatic breast cancer,"A Phase III, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Versus Alpelisib Plus Fulvestrant in Patients With Hormone Receptor-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Who Progressed During or After CDK4/6 Inhibitor and Endocrine Combination Therapy | Unknown | Recruiting | NCT05646862 || A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus a CDK4/6 Inhibitor and Letrozole Versus Placebo Plus a CDK4/6 Inhibitor and Letrozole in Patients With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer | Unknown | Recruiting | NCT06790693 || A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer | Unknown | Recruiting | NCT04191499 || A Phase 1, Open-Label, Single-Dose Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics of Inavolisib | Phase 1 | Recruiting | NCT07144111 || A Randomized, Open-label, Phase II Trial Comparing Neoadjuvant Endocrine Therapy in Combination with Trastuzumab, Pertuzumab +/- the PI3K Inhibitor Inavolisib in Patients with HER2-positive, HR-positive, PIK3CA Mutant Early Breast Cancer-GeparPiPPa | Unknown | Recruiting | NCT05306041 || A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo As Maintenance Therapy After First Line Induction Therapy in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer | Unknown | Recruiting | NCT05894239 || A Phase II, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Neoadjuvant Treatment With Inavolisib Combinations in Patients With Untreated, Early-stage, PIK3CA-Mutated Breast Cancer | Unknown | Recruiting | NCT07054190 || A Phase I/Ib Study Evaluating Single-Agent Inavolisib and Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers | Unknown | Recruiting | NCT06496568 || Phase Ib Clinical Trial of Copanlisib in Combination With Trastuzumab Emtansine (T-DM1) in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer ""Panthera"" | Unknown | Terminated | NCT04042051 || Phase Ib Clinical Trial of Loncastuximab and Roflumilast Added to R-CHOP (Lo-RR-CHOP) for Treatment Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL) | Unknown | Recruiting | NCT06977711 || Phase Ⅱ Study of S-1 Combined With Oxaliplatin (SOX)Verse S-1 Combined With Cisplatin(SP) in Adjuvant Chemotherapy After D2 Surgery | Unknown | Unknown | NCT01679340"
Roche/Genentech,MOSUNETUZUMAB,Lunsumio,Y,2024-12-04,Monoclonal Antibody,CD20 | CD3,Monoclonal Antibody,adult patients with relapsed or refractory follicular lymphoma | adult patients with relapsed or refractory follicular lymphoma | the treatment of adult patients with relapsed or refractory follicular lymphoma | the treatment of adult patients with relapsed or refractory follicular lymphoma | for the treatment of adult patients with relapsed or refractory follicular lymphoma | for the treatment of adult patients with relapsed or refractory follicular lymphoma,"ctDNA-Guided Mosunetuzumab Consolidation Therapy in Older Patients With Untreated DLBCL | Unknown | Recruiting | NCT06828991 || A Pilot Study Evaluating the Safety and Efficacy of Mosunetuzumab Consolidation Therapy After Autologous Stem Cell Transplantation in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma | Unknown | Recruiting | NCT05412290 || A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma (r/r FL) | Unknown | Recruiting | NCT07031700 || A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma | Phase 2 | Recruiting | NCT06563505 || An Open-Label, Multicenter, Phase II Trial Evaluating the Safety, Efficacy, and Pharmacokinetics of Subcutaneous Mosunetuzumab Monotherapy in Patients With Select B-Cell Malignancies | Unknown | Recruiting | NCT05207670 || Phase II Study of Dual Targeting of CD19 and CD20 Antigens Using Sequential CD19-directed CAR-T Cells Followed by Mosunetuzumab or Glofitamab in Relapsed or Refractory Diffuse Large B-cell or Transformed Follicular Lymphomas | Unknown | Recruiting | NCT04889716 || A Phase IB Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | Unknown | Recruiting | NCT05091424 || Phase II Trial of Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma (EMZL) (ML44933) | Unknown | Recruiting | NCT06569680 || BrUOG 401: A Phase 2 Study of Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma | Phase 2 | Recruiting | NCT04792502 || Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma | Unknown | Recruiting | NCT06337318 || A Phase 1 Study of Mosunetuzumab With Polatuzumab Vedotin and Lenalidomide (M+Pola+Len) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 1 | Recruiting | NCT06015880 || An Open-Label, Randomized, Multicenter, Phase Ib/II Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in Patients With B-Cell Non-Hodgkin Lymphoma | Unknown | Recruiting | NCT03671018 || Phase III Randomized, Open-Label, Multicenter Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a Non-Randomized Single Arm US Extension of Mosunetuzumab in Combination With Lenalidomide in Patients With Follicular Lymphoma After at Least One Line of Systemic Therapy | Unknown | Recruiting | NCT04712097 || Low Dose Mosunetuzumab for Indolent B-Cell Lymphoma | Unknown | Recruiting | NCT06442475 || A Phase Ib/II, Open-Label, Multicenter Study With a Non-Randomized Stage Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab Plus Lenalidomide (+Len), and a Randomized Stage Evaluating the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Patients With Follicular Lymphoma | Unknown | Recruiting | NCT04246086 || A Randomized, Open-Label, Multicenter Phase III Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin in Comparison With Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma | Unknown | Recruiting | NCT05171647 || An Open-Label, Multicenter, Single-Arm, Sequential Phase-2 Study of Mosunetuzumab Alone or With Zanubrutinib for the Treatment of Patients With Newly Diagnosed Follicular Lymphoma in Need of Systemic Therapy | Unknown | Recruiting | NCT05389293"
Daiichi Sankyo,Trastuzumab,Enhertu,Y,2025-07-10,Chemotherapy,HER2,,locally advanced or metastatic breast cancer | locally advanced or metastatic breast cancer | positive early breast cancer | positive early breast cancer who have residual invasive disease | overexpressing metastatic gastric | overexpressing breast cancer | overexpressing breast cancer | overexpressing metastatic breast cancer | overexpressing metastatic breast cancer | or in the neoadjuvant or adjuvant setting and have developed disease | adult patients with unresectable or metastatic hepatocellular carcinoma | in the metastatic | that has progressed on one or more endocrine therapies in the metastatic | stage small cell lung cancer | adult patients with metastatic NSCLC whose tumor | stage small cell lung cancer | adult patients with unresectable or metastatic non-small cell | adult patients with locally advanced or metastatic | month of age with solid tumor | the treatment of adult patients with unresectable or metastatic hepatocellular carcinoma | the treatment of adult patients with unresectable or metastatic non-small cell | the treatment of adult patients with locally advanced or metastatic | for the treatment of adult patients with unresectable or metastatic hepatocellular carcinoma | for the treatment of adult patients with unresectable or metastatic non-small cell | for the treatment of adult patients with locally advanced or metastatic,"Prospective Observational Study of Trastuzumab Emtansine Immediately After Trastuzumab Deruxtecan in Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in Korea | Unknown | Recruiting | NCT06928818 || A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1 (DESTINY-Breast01) | Phase 2 | Terminated | NCT03248492 || A Phase I/II Study of Palbociclib, Letrozole and T-DM1 in Trastuzumab Refractory Estrogen Receptor Positive (ER+) and HER2 Positive Metastatic Breast Cancer | Unknown | Terminated | NCT03709082 || Trastuzumab-emtansine and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC | Unknown | Terminated | NCT03784599 || A Randomized, Multicenter, Open Label Study of MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in Anthracycline Naive Patients With Locally Advanced/Metastatic HER2-Positive Breast Cancer | Unknown | Terminated | NCT02213744 || A Study of the Natural History of Ado-trastuzumab Emtansine (T-DM1)-Induced Peripheral Neuropathy in HER2-positive Breast Cancer Patients | Unknown | Recruiting | NCT05889988 || Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease | Unknown | Recruiting | NCT05388149 || Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib | Unknown | Recruiting | NCT05323955 || Chemotherapy-Free pCR-Guided Strategy With Subcutaneous Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer (PHERGAIN-2) | Unknown | Recruiting | NCT04733118 || A Phase III Multicenter, Randomized, Open-label, Active-Controlled Study of SHR-A1811 With or Without Pertuzumab Versus Trastuzumab, Pertuzumab and Docetaxel in HER2-Positive Recurrent or Metastatic Breast Cancer | Unknown | Recruiting | NCT06057610 || Short-course Trastuzumab, Pertuzumab Combined with Taxanes in the Adjuvant Treatment of Early Human Epidermal Growth Factor Receptor 2-positive Breast Cancer: an Open-label, Single-arm Study | Unknown | Recruiting | NCT05891561 || Phase I Trial of a Chimeric (Trastuzumab-like and Pertuzumab-like) HER2 B Cell Peptide Vaccine Emulsified in ISA 720 Adjuvant for Locally Advanced HER2 Positive Breast Cancer | Unknown | Recruiting | NCT06949410 || A Prospective Study of Early Stage Breast Cancer Patients With Abnormal Myocardial Deformation Treated With Anthracycline and/or Trastuzumab and Pertuzumab-based Cancer Therapy | Unknown | Recruiting | NCT02993198 || Cardiotoxicity in Metastatic Her 2 Positive Patients Treated With First Line Trastuzumab, Pertuzumab and Taxanes Based Regimen | Unknown | Unknown | NCT02101879 || Phase 2, Multi-Center, Randomized, Open-Label Trial of BDC-1001 as a Single Agent and in Combination With Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer Previously Treated With Trastuzumab Deruxtecan | Phase 2 | Terminated | NCT05954143 || FDA Approval History: Trastuzumab | Unknown | Active | NCT02564900 || A Single-center, Prospective, Single Arm Study of Neoadjuvant Treatment With Pegylated Liposomal Doxorubicin（PLD）Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast Cancer | Unknown | Unknown | NCT03994107 || A Phase 2 Study to Evaluate TL938 Combined With Trastuzumab in Patients With HER2-positive Metastatic Colorectal Cancer | Phase 2 | Recruiting | NCT06589830 || Phase I Trial of CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer | Unknown | Recruiting | NCT05187182 || A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors | Phase 1 | Recruiting | NCT05143970 || Generation of Induced Pluripotent Stem Cell Derived Cardiomyocytes From Patients Exposed to Trastuzumab Therapy for Breast Cancer | Unknown | Recruiting | NCT02772367 || A Randomised Phase III Study of Trastuzumab-Docetaxel vs Trastuzumab-Vinorelbine as 1. Line Therapy for Patients With Metastatic HER2 Positive Breast Cancer | Unknown | Unknown | NCT00430001 || A Randomized, Open-label Study of First Line Pyrotinib, Trastuzumab With an Aromatase Inhibitors, in the Treatment of HER2 Positive and HR Positive Metastatic or Inoperable Locally Advanced Breast Cancer | Unknown | Unknown | NCT03910712 || Study Phase II ""Proof of Concept"", National Multi-centered. Randomised 1:1, Evaluate Whether Dapagliflozin Reduces Chemotherapy Induced Cardiotoxicity in Participants With Breast Cancer Treated With (Neo-) Adjuvant Anthracycline-based Chemotherapy +/- Trastuzumab | Unknown | Recruiting | NCT06341842 || TRUDI: A Phase II Study of Neoadjuvant Trastuzumab Deruxtecan and Durvalumab for Stage III, HER2-expressing Inflammatory Breast Cancer | Unknown | Recruiting | NCT05795101 || A Multi-Center Phase I Trial of Neratinib and Fam-trastuzumab Deruxtecan in Advanced Refractory Gastric and Esophageal Cancer Patients | Unknown | Recruiting | NCT05274048 || HER2 Heterogeneity and Its Impact on Benefit from Trastuzumab Deruxtecan in Metastatic Breast Cancer | Unknown | Recruiting | NCT06551220 || Real World Study of TrEatment Discontinuations and Modifications for Patients With HER2+ and HER2-low Metastatic Breast Cancer On Trastuzumab Deruxtecan | Unknown | Recruiting | NCT06386263 || Efficacy and Safety of Disitamab Vedotin (RC48) in Combination With Bevacizumab or Pyrotinib in Patients With HER2-Positive Metastatic Breast Cancer After Trastuzumab Deruxtecan (T-DXd) Treatment Failure: A Phase II Study | Unknown | Recruiting | NCT07065435 || An Open-label, Single-arm, Phase 2 Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd) for Patients With HER2-mutant Metastatic NSCLC Who Have Disease Progression on or After at Least One-line of Treatment (DESTINY-Lung05) | Phase 2 | Recruiting | NCT05246514 || Single Arm Phase 2 Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer: a Standard Chemotherapy-sparing Approach to Curative-intent Treatment - SHAMROCK Study | Phase 2 | Recruiting | NCT05710666 || Identification Of Toxicity Markers to Trastuzumab-Deruxtecan (T-DXd) In Patients With Advanced Breast Cancer. Tox-DXd: a Prospective, Observational Study | Unknown | Recruiting | NCT07049133 || DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig Versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer | Unknown | Recruiting | NCT06467357 || A Phase 1/2, Open Label Trial to Investigate the Safety, Tolerability, and Preliminary Efficacy of EIS-12656 as Single Agent and in Combination With a Poly-ADP Ribose Polymerase (PARP) Inhibitor or Trastuzumab Deruxtecan (T-DXd), an Antibody Drug Conjugate (ADC), in Participants With Specified Solid Tumors | Phase 1 | Recruiting | NCT06525298 || A Phase II, Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of Trastuzumab Deruxtecan (DS-8201a) With or Without Anastrozole for HER2 Low Hormone Receptor Positive (HR+) Breast Cancer in the Neoadjuvant Setting | Unknown | Recruiting | NCT04553770 || A Randomized Phase II Study to Evaluate the Safety and Efficacy of Trastuzumab Deruxtecan Versus CDK4/6 Inhibitor-based Endocrine Therapy as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype According to Gene Expression Profiling. | Unknown | Recruiting | NCT06486883 || Open-label Single-arm Phase 2 Trial of Trastuzumab Deruxtecan in Previously Treated HER2-Immunohistochemistry (IHC) 0 Advanced Breast Cancer | Phase 2 | Recruiting | NCT06750484 || TBCRC 023: A Randomized Multicenter Phase II Neoadjuvant Trial of Lapatinib Pus Trastuzumab, With or Without Endocrine Therapy for 12 Weeks vs. 24 Weeks in Patients With HER2 Overexpressing Breast Cancer | Unknown | Recruiting | NCT00999804 || A Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of Patients With HER2/Neu+ Breast Cancer Who Have Failed Trastuzumab and Chemotherapy Including a Taxane | Phase 2 | Terminated | NCT00657137"
Roche/Genentech,GLOFITAMAB,Columvi,Y,2025-06-18,Prescription Drug,CD20 | CD3,,cell lymphoma | arising from follicular lymphoma | adult patients with relapsed or refractory diffuse large B-cell | or large B-cell | adult patients with relapsed or refractory follicular lymphoma | the treatment of adult patients with relapsed or refractory diffuse large B-cell | the treatment of adult patients with relapsed or refractory follicular lymphoma | for the treatment of adult patients with relapsed or refractory diffuse large B-cell | for the treatment of adult patients with relapsed or refractory follicular lymphoma,"A Phase 2 Study of Glofitamab and Obinutuzumab for First-line Treatment of Follicular Lymphoma and Marginal Zone Lymphoma | Phase 2 | Recruiting | NCT05783596 || A Phase IB, Open-Label, Multicenter, Single Arm Study Evaluating the Preliminary Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Patients With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma | Unknown | Recruiting | NCT05364424 || A Multicenter Phase 2 Study of Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma | Phase 2 | Recruiting | NCT06252675 || A Phase II Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma | Unknown | Recruiting | NCT06071871 || Phase II Study of Glofitamab, Poseltinib and Lenalidomide in Patients with Relapsed/refractory Diffuse Large B Cell Lymphoma | Unknown | Recruiting | NCT05335018 || The Efficacy and Safety of Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab Monoclonal Antibody in the Treatment of Refractory Relapsed Diffuse Large B-cell Lymphoma Patients | Unknown | Recruiting | NCT06651853 || A Multicenter, Open-label, Phase I/II Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of Escalating Doses of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab Administered After a Fixed, Single Dose Pre-treatment of Obinutuzumab (Gazyva®/Gazyvaro™) in Patients With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma | Unknown | Recruiting | NCT03075696 || A Prospective, Observational Study to Explore the Efficacy and Safety of Salvage Therapy With Glofitamab in a Real-world Setting in Chinese Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma. | Unknown | Recruiting | NCT06497452 || A PHASE 1b/2, OPEN-LABEL STUDY OF PF-07901801 IN COMBINATION WITH GLOFITAMAB AFTER A FIXED, SINGLE DOSE OF OBINUTUZUMAB IN PARTICIPANTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION | Phase 1 | Recruiting | NCT05896163 || A Phase II, Multicenter, Open-label Study Evaluating Glofitamab in Combination With Venetoclax Plus Zanubrutinib or Venetoclax Alone in Subjects With Untreated or Relapsed/Refractory High-risk Mantle-cell Lymphoma | Unknown | Recruiting | NCT06558604 || A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma | Unknown | Recruiting | NCT05800366 || A Phase 2 Trial of Glofitamab for Minimal Residual Disease in Patients With Large B-cell Lymphoma | Phase 2 | Withdrawn | NCT06670105 || A Phase 2 Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma | Phase 2 | Recruiting | NCT06213311 || A Phase III, Open-Label, Multicenter Randomized Study Evaluating Glofitamab as a Single Agent Versus Investigator's Choice in Patients With Relapsed/Refractory Mantle Cell Lymphoma | Unknown | Recruiting | NCT06084936 || A Phase II Trial Evaluating Glofitamab, a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy | Unknown | Recruiting | NCT04703686 || A Phase II, Open-Label, Multicenter Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Unknown | Recruiting | NCT06806033 || A Multicentre Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL) | Unknown | Recruiting | NCT04914741"
Roche/Genentech,ALECTINIB HYDROCHLORIDE,ALECENSA,Y,2024-04-30,Kinase Inhibitor,ALK | MET | ERK | ATM | ATR,Kinase Inhibitor,positive metastatic | stage small cell lung cancer | stage small cell lung cancer | Positive Non-Small Cell | as adjuvant treatment in adult patients following tumor resection of anaplastic lymphoma,
Roche/Genentech,COBIMETINIB,Cotellic,Y,2024-11-18,Kinase Inhibitor,MEK,Kinase Inhibitor,adult patients with unresectable or metastatic melanoma | adult patients with unresectable or metastatic hepatocellular carcinoma | adult patients with histiocytic neoplasm | the treatment of adult patients with unresectable or metastatic melanoma | the treatment of adult patients with unresectable or metastatic hepatocellular carcinoma | the treatment of adult patients with histiocytic neoplasm | for the treatment of adult patients with unresectable or metastatic melanoma | for the treatment of adult patients with unresectable or metastatic hepatocellular carcinoma | for the treatment of adult patients with histiocytic neoplasm,"Randomized Phase II Trial of Vemurafenib (PLX4032/RG7204)/Cobimetinib (GDC-0973) With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma | Unknown | Terminated | NCT01495988 || Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases | Unknown | Active | NCT02230306 || A Phase II, Open-Label, Multicenter Study of Vemurafenib Plus Cobimetinib (GDC-0973) in Unresectable Stage IIIc or Stage IV Melanoma; Response Monitoring and Resistance Prediction With Positron Emission Tomography and Tumor Characteristics | Unknown | Terminated | NCT02414750 || A Phase I, Open-Label, Dose Finding Study of Calaspargase Pegol-Mnkl in Combination With Cobimetinib in Locally-Advanced or Metastatic Pancreatic Cancer | Unknown | Recruiting | NCT05034627"
Roche/Genentech,ENTRECTINIB,Rozlytrek,Y,2024-11-20,Kinase Inhibitor,ALK | ROS1 | NTRK,Kinase Inhibitor,stage small cell lung cancer | stage small cell lung cancer | positive metastatic non-small cell | positive metastatic | month of age with solid tumor | are metastatic,"Randomized, Open Label, Multicenter, Phase III Study of Entrectinib Versus Crizotinib in Patients With Locally-Advanced or Metastatic Non-Small Cell Lung Cancer Harboring ROS1 Gene Rearrangements With and Without Central Nervous System Metastases | Unknown | Recruiting | NCT04603807 || A Phase 1/2, Open-Label, Dose-Escalation And Expansion Study Of Entrectinib (Rxdx-101) In Pediatrics With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options | Phase 1 | Recruiting | NCT02650401 || PHASE 2 Study of Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors (GLOBOTRK) | Phase 2 | Recruiting | NCT06528691 || A Phase I Study of Entrectinib in Combination With ASTX727 (35 mg Decitabine and 100 mg Cedazuridine) in Patients With Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia (AML) | Unknown | Suspended | NCT05396859 || An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements | Phase 2 | Recruiting | NCT02568267 || DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations. Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-positive Cancers. | Unknown | Recruiting | NCT05770544 || Phase 1B/2 Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma | Phase 1 | Terminated | NCT04589832 || Expanded Access to Entrectinib (RXDX-101) for the Treatment of Cancers With NTRK, ROS1, or ALK Gene Fusions | Unknown | Unknown | NCT03066661"
Roche/Genentech,PERTUZUMAB,Phesgo,Y,2024-12-02,Chemotherapy,HER2 | MET | RET | ATM | ATR,,positive metastatic breast cancer | therapy or chemotherapy for metastatic disease | positive metastatic | therapy or chemotherapy for metastatic disease | or early stage breast cancer | complete treatment regimen for early breast cancer | complete treatment regimen for early breast cancer | locally advanced or metastatic breast cancer | positive early breast cancer | positive early breast cancer | locally advanced or metastatic breast cancer | positive breast cancer | positive breast cancer | positive locally advanced | positive early breast cancer who had their primary tumor | overexpressing early breast cancer | overexpressing early breast cancer,"A Phase Ib/II Multicenter, Open-Label Clinical Trial of SHR-A1811 Injection in Combination With Pyrotinib or Pertuzumab or Adebrelimab or Paclitaxel for Injection (Albumin Bound) in Breast Cancer | Unknown | Recruiting | NCT05353361"
Roche/Genentech,VEMURAFENIB,ZELBORAF,Y,2024-11-08,Kinase Inhibitor,BRAF,Kinase Inhibitor,adult patients with unresectable or metastatic melanoma | adult patients with unresectable or metastatic hepatocellular carcinoma | Chester Disease | type BRAF melanoma | the treatment of patients with unresectable or metastatic melanoma | the treatment of patients with unresectable or metastatic melanoma | for the treatment of patients with unresectable or metastatic melanoma | for the treatment of patients with unresectable or metastatic melanoma,"A Phase I, Single Arm, Dose Escalation Study to Evaluate Safety, Pharmacokinetics and Preliminary Efficacy of HL-085 Plus Vemurafenib in Patients With BRAF V600 Mutant Advanced Solid Tumor | Unknown | Unknown | NCT03781219 || Phase I Dose Escalation of the MET Inhibitor XL184 and the BRAF Inhibitor Vemurafenib | Unknown | Terminated | NCT01835184 || A Single Center Phase II Trial of Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation | Unknown | Active | NCT01474551 || An Open Label Multicenter, Phase I-II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation and Pharmacokinetics of PD-0332991 in Patients Suffering Metastatic Melanoma With BRAFv600 Mutated and CDKN2A Loss and Expression of Rb and Treated by Vemurafenib | Unknown | Unknown | NCT02202200 || A Single-arm, Open, Multicenter Phase II Study to Evaluate the Efficacy and Safety of HL-085 Capsules Combined With Vemurafenib in the Treatment of BRAF V600E Mutated Patients With Unresectable Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) | Unknown | Recruiting | NCT05900219 || VIC Regimen (Vemurafenib/Irinotecan/Cetuximab) Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Advanced Colorectal Cancer | Unknown | Unknown | NCT05540951 || Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations | Phase 2 | Recruiting | NCT02304809 || A Phase I Trial of Vemurafenib and Ipilimumab in Subjects With V600 BRAF Mutation-positive Metastatic Melanoma | Unknown | Active | NCT01400451"
AbbVie Inc.,VENETOCLAX,Venclexta,Y,2024-07-12,Vaccine,ALK | MET | RET | ERK | ATM | ATR | BCL-2,,adult patients with chronic lymphocytic leukemia | or small lymphocytic lymphoma | newly diagnosed acute myeloid leukemia | the treatment of adult patients with chronic lymphocytic leukemia | for the treatment of adult patients with chronic lymphocytic leukemia | dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia,"An Open, Prospective, Single-arm Study of Olverembatinib Plus Venetoclax and Dexamethasone in Patients of Newly-diagnosed Ph+ Acute Lymphoblastic Leukemia | Unknown | Recruiting | NCT06082934 || A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Induction Chemotherapy | Unknown | Recruiting | NCT05503355 || A Bioavailability and Food Effect Study of Venetoclax New Tablet Formulation 2.0 in Healthy Female Subjects | Unknown | Recruiting | NCT06742086 || A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy) | Phase 2 | Recruiting | NCT06561074 || A Phase 4 Study of Venetoclax in Combination With Azacitidine in Newly Diagnosed Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy in China | Unknown | Recruiting | NCT05144243 || CC-486 and Venetoclax for Acute Myeloid Leukemia | Unknown | Recruiting | NCT05287568 || Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Course in the Treatment of Acute Myeloid Leukemia With Venetoclax: The Venetoclax Registry | Unknown | Recruiting | NCT03662724 || First Line Treatment With VeNEtoclaX and ibruTinib Induction Followed by Obinutuzumab intenSificaTion Exclusively in CLL/SLL Patients Not in Complete Remission and/or With Detectable Bone Marrow Minimal Residual Disease (NEXT STEP Trial) | Unknown | Recruiting | NCT04639362 || A Phase IB/II Study of Venetoclax (ABT-199) in Combination With Liposomal Vincristine or Vincristine Sulfate in Patients With Relapsed or Refractory T-Cell or B-Cell Acute Lymphoblastic Leukemia | Unknown | Recruiting | NCT03504644 || A Phase I Study of Venetoclax to Augment Epigenetic Modification and Chemotherapy in Pediatric and Young Adult Patients With Relapsed and Refractory Acute Myeloid Leukemia | Unknown | Recruiting | NCT05317403 || Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia | Unknown | Recruiting | NCT05660473 || Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma | Phase 1 | Recruiting | NCT04739813 || A Phase 2 Study of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) for Initial Therapy of Chronic Lymphocytic Leukemia | Phase 2 | Recruiting | NCT03580928 || Phase 2 Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) and Mantle Cell Lymphoma (MCL) | Phase 2 | Recruiting | NCT03824483 || A Multicenter, Prospective, Phase II Study of Decitabine, Venetoclax and Blinatumomab for Maintenance Following Allogeneic Hematopoietic Cell Transplantation in Patients With Ph-Negative B-Cell Acute Lymphoblastic Leukemia | Unknown | Recruiting | NCT06393985 || A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | Phase 1 | Recruiting | NCT05520567 || A Multi-center, Single-arm Trial of the Efficacy of a Triple Regimen Including Gilteritinib, Venetoclax, and Azacitidine in Newly Diagnosed Fit AML Patients With FLT3 Mutation | Unknown | Recruiting | NCT06561880 || VenBom: a Phase 1 Study of Bomedemstat (IMG-7289), a Novel Inhibitor of Lysine-Specific Demethylase 1 (LSD1), in Combination with Venetoclax in Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) | Phase 1 | Suspended | NCT05597306"
Roche/Genentech,VISMODEGIB,ERIVEDGE,Y,2024-12-02,Prescription Drug,THE,,adults with metastatic basal cell carcinoma | or with locally advanced basal cell carcinoma | or with locally advanced basal cell carcinoma | the treatment of adults with metastatic basal cell carcinoma | the treatment of adults with metastatic basal cell carcinoma | for the treatment of adults with metastatic basal cell carcinoma | for the treatment of adults with metastatic basal cell carcinoma,"A Randomized, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Oral Vismodegib for the Treatment of Basal Cell Carcinoma Preceding Excision by Mohs Micrographic Surgery | Unknown | Terminated | NCT01898598 || Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia | Unknown | Terminated | NCT01944943 || A Placebo Controlled Double-Blind Study to Evaluate the Efficacy of Vismodegib as Chemoprevention of New Bcc Development in High Risk Subjects | Unknown | Active | NCT02067104 || A Study of Oral Vismodegib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) | Unknown | Withdrawn | NCT02168530 || A Randomized Phase II Pilot Study to Evaluate Safety and Efficacy of the Addition of Vismodegib to Standard Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Patients | Unknown | Unknown | NCT02694224"
Amneal Pharmaceuticals LLC,BEVACIZUMAB,ALYMSYS,Y,2022-04-23,Therapeutic Protein,VEGF,Therapeutic Protein,recurrent glioblastoma (GBM) in adults | metastatic renal cell carcinoma | or metastatic cervical cancer | adult patients with unresectable or metastatic hepatocellular carcinoma | or primary peritoneal cancer | colon cancer | patients with metastatic colorectal cancer | patients with metastatic colorectal cancer | adult patients with metastatic NSCLC who have disease | stage small cell lung cancer | stage small cell lung cancer | locally advanced or metastatic breast cancer | recurrent or metastatic | month of age with solid tumor | adjuvant treatment of colon cancer | line treatment of patients with metastatic colorectal cancer | line treatment of patients with metastatic colorectal cancer | line treatment of patients with metastatic colorectal cancer | the treatment of metastatic renal cell carcinoma | the treatment of metastatic renal cell carcinoma | for the treatment of metastatic renal cell carcinoma | for the treatment of metastatic renal cell carcinoma | fallopian tube or primary peritoneal cancer | squamous non-small cell | the treatment of patients with unresectable or metastatic hepatocellular carcinoma | the treatment of patients with unresectable or metastatic hepatocellular carcinoma | the treatment of patients with unresectable or metastatic melanoma | for the treatment of patients with unresectable or metastatic hepatocellular carcinoma | for the treatment of patients with unresectable or metastatic hepatocellular carcinoma | for the treatment of patients with unresectable or metastatic melanoma,"Efficacy and Biomarker Explanation of IBI-323 Combined With Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged Non-Small Cell Lung Cancer Who Failed From First Line Alectinib | Unknown | Recruiting | NCT05296278 || Phase I/II Trial Of Super-Selective Intraarterial Infusion Of Erbitux (Cetuximab) And Avastin (Bevacizumab)For Treatment Of Relapsed/Refractory Intracranial Glioma In Patients Under 22 Years Of Age | Unknown | Terminated | NCT01884740 || Safety and Efficacy of Nivolumab Combined With CAPOX Plus Bevacizumab as Neoadjuvant Treatment of pMMR/MSS Colorectal Cancer Liver Metastases Patients：a Single-arm, Phase II, Prospective Study | Unknown | Recruiting | NCT05588297 || A Phase II Study of Bevacizumab (rhuMab VEGF, NSC 704865), Idarubicin and Cytarabine in Patients With Chronic Myeloid Leukemia in Blast Phase | Unknown | Terminated | NCT00023920 || Single-arm Phase II Study of Bevacizumab Plus Modified FOLFIRINOX Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Mucinous Carcinoma | Unknown | Unknown | NCT05665023 || A Phase II Two Cohorts Prospective Study to Evaluate the Efficacy and Safety of Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in Non-squamous NSCLC With EGFR Sensitizing Mutation Who Failed EGFR TKI Therapy | Unknown | Unknown | NCT04405674 || Phase II Trial of Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer | Unknown | Withdrawn | NCT03836157 || A Study of Safety, Tolerability, and Clinical Activity of Durvalumab and Tremelimumab Administered as Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Subjects With Advanced Hepatocellular Carcinoma | Unknown | Recruiting | NCT02519348 || Bevacizumab Combined With Gefitinib in the Treatment of Advanced NSCLC Clinical Study of L858R Positive Mutation Patients | Unknown | Unknown | NCT04425187 || A Multicenter, Open-label Phase I/II Trial Aiming to Assess the Safety and Clinical Activity of Bemarituzumab + Bevacizumab in Advanced/Metastatic Gynecological Cancer Overexpressing FGFR2b | Unknown | Recruiting | NCT07146919 || Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301) | Unknown | Recruiting | NCT06252649 || Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases: mFOLFOXIRI Plus Cetuximab Versus mFOLFOXIRI Plus Bevacizumab | Unknown | Recruiting | NCT04687631 || Panitumumab and Bevacizumab Maintenance After First-Line FOLFOX-Bevacizumab for Patients With Advanced Colorectal Cancer With Wild-Type Ras | Unknown | Terminated | NCT01057017 || A Randomised Phase II/III Trial of Peri-Operative Chemotherapy With or Without Bevacizumab in Operable Oesophagogastric Adenocarcinoma and A Feasibility Study Evaluating Lapatinib in HER-2 Positive Oesophagogastric Adenocarcinomas and (in Selected Centres) MRI and PET/CT Sub-studies | Unknown | Unknown | NCT00450203 || Randomized Phase III Trial Comparing Everolimus Versus Everolimus Plus Bevacizumab for Advanced Renal Cell Carcinoma Progressing After Treatment With Tyrosine Kinase Inhibitors | Unknown | Terminated | NCT01198158"
Roche/Genentech,OBINUTUZUMAB,Gazyva,Y,2023-08-23,Therapeutic Protein,ALK | MET | ERK | DGK | ATM | ATR | CD20,Therapeutic Protein,patients with previously untreated chronic lymphocytic leukemia | patients with follicular lymphoma | or are refractory | III or IV follicular lymphoma | follicular lymphoma and chronic lymphocytic leukemia | the treatment of patients with previously untreated chronic lymphocytic leukemia | the treatment of patients with follicular lymphoma | for the treatment of patients with previously untreated chronic lymphocytic leukemia | for the treatment of patients with follicular lymphoma,"Two-arm Phase II Trial Exploring the Use of the Targeted Agents Ibrutinib and Obinutuzumab for the Treatment of Patients With a Diagnosis of Richter's Transformation (RT) or Richter's Syndrome (RS) | Unknown | Terminated | NCT03145480 || A Phase 1b Clinical Study of Lenalidomide in Combination With Zanubrutinib and Obinutuzumab (ZGR) in the Treatment of Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) With Therapeutic Indications | Phase 1 | Recruiting | NCT06547944 || Obinutuzumab in the Management of Idiopathic Membranous Nephropathy | Unknown | Unknown | NCT05845762 || Multicenter Phase II Study of the Bendamustine, Obinutuzumab, and Dexamethasone (BOD) Regimen in Un-fit Elderly ≥ 70 Years of Age Diffuse Large B-Cell Non-Hodgkin Lymphoma (DLBCL) Patients | Unknown | Terminated | NCT02420210 || A Prospective, Open-label, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of Obinutuzumab(GA101) in Combination With Lenalidomide in Relapsed and Refractory(R/R) Marginal Zone Lymphoma (MZL) | Unknown | Recruiting | NCT05846750 || A Phase 1 Trial of Naptumomab Estafenatox (NAP) in Combination With Pembrolizumab (Pembro) Preceded by Obinutuzumab (Obi) in Patients With Urothelial Cancers | Phase 1 | Withdrawn | NCT05894447 || A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination With Chlorambucil, Acalabrutinib (ACP-196) in Combination With Obinutuzumab, and Acalabrutinib Monotherapy in Subjects With Previously Untreated CLL | Unknown | Recruiting | NCT02475681 || Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma：a Multicenter Prospective Single Arm Trial | Unknown | Recruiting | NCT06454968"
Roche/Genentech,RITUXIMAB,Rituxan,Y,2025-01-06,Therapeutic Protein,CD20,Therapeutic Protein,adult patients with relapsed or refractory follicular lymphoma | active rheumatoid arthritis | the rate of infection | MPA who have Achieved Disease | adult patients with: Non-Hodgkin's Lymphoma (NHL) ( 1 | active rheumatoid arthritis who have had an inadequate response to one or more Tumor | cell lymphoma | Burkitt lymphoma | like lymphoma | cell acute leukemia | positive diffuse large B-cell | or mature B-cell,"FDA Comprehensive Approval: Rituxan | Phase 2 | Active | NCT00074438 || FDA Comprehensive Approval: Rituxan | Phase 2 | Active | NCT01613599 || FDA Comprehensive Approval: Rituxan | Phase 2 | Active | NCT00468546 || FDA Comprehensive Approval: Rituxan | Phase 2 | Active | NCT02097745 || FDA Comprehensive Approval: Rituxan | Phase 2 | Active | NCT02093026 || FDA Comprehensive Approval: Rituxan | Phase 2 | Active | NCT02383589 || FDA Comprehensive Approval: Rituxan | Phase 2 | Active | NCT00281918 || FDA Comprehensive Approval: Rituxan | Phase 2 | Active | NCT02693210 || FDA Comprehensive Approval: Rituxan | Phase 2 | Active | NCT00748644 || FDA Comprehensive Approval: Rituxan | Phase 2 | Active | NCT00003150 || FDA Comprehensive Approval: Rituxan | Phase 2 | Active | NCT00299130 || FDA Comprehensive Approval: Rituxan | Phase 2 | Active | NCT00282308 || FDA Comprehensive Approval: Rituxan | Phase 2 | Active | NCT00090051 || FDA Comprehensive Approval: Rituxan | Phase 2 | Active | NCT00104299 || FDA Comprehensive Approval: Rituxan | Phase 2 | Active | NCT00064116 || FDA Comprehensive Approval: Rituxan | Phase 2 | Active | NCT00016874 || FDA Comprehensive Approval: Rituxan | Phase 2 | Active | NCT00784589 || FDA Comprehensive Approval: Rituxan | Phase 2 | Active | NCT01750697 || FDA Comprehensive Approval: Rituxan | Phase 2 | Active | NCT00422383 || FDA Comprehensive Approval: Rituxan | Phase 2 | Active | NCT00266227 || Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL) | Unknown | Terminated | NCT03136497 || Rituximab-induced Pulmonary Function Changes - an Observational Study in Patients With Rheumatoid Arthritis and Inflammatory Myositis | Unknown | Unknown | NCT01632124 || Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL) ：a Single Arm, Open Label, Multi-center Phase II Study | Unknown | Unknown | NCT04989621 || A Multicenter, Phase I, Open-label, Uncontrolled Study of ONO-4059 in Combination With Rituximab, Methotrexate, Procarbazine, and Vincristine (R-MPV) Therapy for Untreated Primary Central Nervous System Lymphoma (PCNSL) | Unknown | Recruiting | NCT06541665 || A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Polatuzumab Vedotin in Combination With Rituximab and CHP (R-CHP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With Diffuse Large B-Cell Lymphoma | Unknown | Recruiting | NCT03274492 || Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma | Unknown | Recruiting | NCT01856192 || A Phase 2 Study of Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma | Phase 2 | Recruiting | NCT03789240 || A Phase I/II Trial of Rituximab, Bendamustine, and Obatoclax in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma | Unknown | Withdrawn | NCT01238146 || A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With Rituximab and Lenalidomide (R2) Compared to R2 in Subjects With Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1) | Unknown | Recruiting | NCT05409066 || A Phase II Open-Label, Multi-Centre Study of Minimal Residual Disease-Directed Consolidation With Epcoritamab or Epcoritamab-Lenalidomide-Rituximab Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma (EpLCART) | Unknown | Recruiting | NCT06414148 || A Phase 2 Study Evaluating Epcoritamab in Subjects With Relapsed and Refractory Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab | Phase 2 | Recruiting | NCT06931652 || Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma | Phase 2 | Recruiting | NCT06045247 || A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) Compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2) | Unknown | Recruiting | NCT06191744 || A Phase I Study of Moxetumomab Pasudotox-tdfk (Lumoxiti (TM)) and Either Rituximab (Rituxan (R)) or Ruxience for Relapsed Hairy Cell Leukemia | Unknown | Recruiting | NCT03805932 || A Phase 1b/2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide and Epacadostat (INCB024360) in Patients With Recurrent Ovarian Cancer | Phase 1 | Unknown | NCT02785250"
Roche/Genentech,RITUXIMAB AND HYALURONIDASE,Rituxan,Y,2025-07-24,Therapeutic Protein,MET | ATM | ATR | CD20 | B-CELL LYMPHOMA,Therapeutic Protein,adult patients with relapsed or refractory follicular lymphoma | malignant condition | cell lymphoma | adult patients with previously untreated diffuse large B-cell | the treatment of adult patients with previously untreated diffuse large B-cell | for the treatment of adult patients with previously untreated diffuse large B-cell,
"Genmab US, Inc.",EPCORITAMAB,EPKINLY,Y,2024-07-26,Prescription Drug,ALK | MET | RET | ATM | ATR | CD20 | B-CELL LYMPHOMA,,cell lymphoma | including DLBCL arising from indolent lymphoma | adult patients with relapsed or refractory diffuse large B-cell | grade B-cell | adult patients with relapsed or refractory follicular lymphoma | adult patients with relapsed or refractory follicular lymphoma | Lymphoma adult patients with relapsed or refractory diffuse large B-cell | cell Lymphoma adult patients with relapsed or refractory | the treatment of adult patients with relapsed or refractory diffuse large B-cell | the treatment of adult patients with relapsed or refractory follicular lymphoma | the treatment of adult patients with relapsed or refractory follicular lymphoma | for the treatment of adult patients with relapsed or refractory diffuse large B-cell | for the treatment of adult patients with relapsed or refractory follicular lymphoma | for the treatment of adult patients with relapsed or refractory follicular lymphoma,"A Phase II Trial Evaluating Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma | Unknown | Recruiting | NCT05852717 || Multicenter, Randomized Phase II Study of Epcoritamab for Patients With Aggressive B-Cell Lymphomas Achieving a Partial Response After CD19-Directed CAR-T Therapy | Unknown | Recruiting | NCT06238648 || A Single Arm, Open-Label, Phase 1b Trial of Epcoritamab in Pediatric Patients With Relapsed/Refractory Aggressive Mature B-cell Neoplasms | Phase 1 | Recruiting | NCT05206357 || Phase 2 Study of Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma | Phase 2 | Recruiting | NCT06919939 || A Phase 2 Study of Outpatient Epcoritamab As Second Line Therapy in Non-Transplant Eligible Relapsed/Refractory Large B-cell Lymphoma | Phase 2 | Recruiting | NCT06811272 || A Phase Ib Trial With Dose Expansion of Epcoritamab in Combination With Ibrutinib in Refractory/Recurrent CNS Lymphoma (EIFEL-Trial) | Unknown | Recruiting | NCT07082868 || Phase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination With Anti-Neoplastic Agents in Subjects With Non-Hodgkin Lymphoma | Phase 1 | Recruiting | NCT05283720 || A Pilot Study of Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for Upfront Treatment of Aggressive B-Cell Non-Hodgkin Lymphomas | Unknown | Recruiting | NCT07097363 || A Phase 2 Study of Epcoritamab as a Consolidation Therapy for 2nd Generation BTKi +/- Obinutuzumab in CLL/SLL Patients or Variants of This. | Phase 2 | Recruiting | NCT07108998 || Expanded Access to Epcoritamab | Unknown | Unknown | NCT05692050 || A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) | Phase 1 | Recruiting | NCT04663347 || A Phase 3, Multicenter, Randomized, Open-Label Study of Epcoritamab Plus Lenalidomide Compared to Rituximab Plus Gemcitabine and Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Unknown | Recruiting | NCT06508658 || A Phase 2 Study of Epcoritamab and Rituximab for First-line Treatment of Follicular Lymphoma | Phase 2 | Recruiting | NCT05783609 || EpcoReal: A Multi-country, Prospective Observational Study of Epcoritamab in NHL Comprising Two Patient Cohorts (3L+ (D)LBCL and 3L+ FL) | Unknown | Recruiting | NCT06830759"
"ImmunoGen, Inc.",MIRVETUXIMAB SORAVTANSINE,ELAHERE,Y,2025-07-14,Chemotherapy,ALK | MET | ATM,,or primary peritoneal cancer,"FDA Approval History: Mirvetuximab Soravtansine | Unknown | Active | NCT01609556 || FDA Approval History: Mirvetuximab Soravtansine | Unknown | Active | NCT02631876 || A Phase 2, Two-stage, Study of Mirvetuximab Soravtansine (IMGN853) in Combination With Pembrolizumab in Patients With Microsatellite Stable (MSS) Recurrent or Persistent Endometrial Cancer (EC) | Phase 2 | Recruiting | NCT03835819 || Pilot Study of Mirvetuximab Soravtansine (IMGN853) in Folate Receptor Alpha (FRα)-Expressing, Triple Negative Breast Cancer (TNBC) With Residual Disease Post Standard Neoadjuvant Chemotherapy | Unknown | Withdrawn | NCT03045393 || A Phase II Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib in Recurrent Platinum Sensitive Ovarian, Peritoneal, and Fallopian Tube Cancer | Unknown | Recruiting | NCT05887609 || A Randomized Phase 2, Open-label Study of Mirvetuximab Soravtansine in Patients With Platinum-resistant Advanced High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-alpha Expression Testing 2 Schedules of Administration for Dose Optimization, With a Separate Cohort to Determine Starting Dose in Patients With Moderate Hepatic Impairment | Phase 2 | Recruiting | NCT06682988 || A Phase 2, Open-Label, Randomized, Master Protocol Dose Optimization Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations With Mirvetuximab Soravtansine in Subjects With Ovarian Cancer | Phase 2 | Recruiting | NCT07059845 || A Phase II Evaluation of the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Persistent or Recurrent Endometrial Cancer | Unknown | Recruiting | NCT03832361 || Single-Arm Phase II Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer Who Are Folate Receptor α Positive | Unknown | Recruiting | NCT04606914 || A Randomized Phase II Trial of Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer Eligible for Platinum-based Chemotherapy. Supported by: DIAGNOSTIC PROTOCOL for the VENTANA FOLR1 (FOLR1-2.1) CDx Assay Ventana No. RD004881; Protocol Document No. D152967 | Unknown | Recruiting | NCT04274426 || A Single-Arm, Phase 2 Study of Neoadjuvant Carboplatin and Mirvetuximab Soravtansine in Subjects With FRα-Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer | Phase 2 | Recruiting | NCT06890338 || Multicenter, Open-label, Phase 2 Study of Carboplatin Plus Mirvetuximab Soravtansine Followed by Mirvetuximab Soravtansine Continuation in FRα Positive, Recurrent Platinum-sensitive, High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Following 1 Prior Line of Platinum-based Chemotherapy | Phase 2 | Recruiting | NCT05456685 || Randomized, Multicenter, Open-label, Phase 3 Study of Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy for Patients With FRα-high Recurrent Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed After Second Line Platinum-based Chemotherapy Plus Bevacizumab | Unknown | Recruiting | NCT05445778 || A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Patients With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression | Phase 2 | Recruiting | NCT06365853"
AstraZeneca Pharmaceuticals LP,DURVALUMAB,IMFINZI,Y,2025-03-28,Monoclonal Antibody,PD-L1,Monoclonal Antibody,stage small cell lung cancer | mutations or anaplastic lymphoma | adult patients with unresectable Stage III NSCLC whose disease | adult patients with metastatic NSCLC with no sensitizing EGFR mutations or ALK genomic tumor | adult patients with metastatic NSCLC who have disease | adult patients with locally advanced or metastatic biliary tract cancer | adult patients with locally advanced or metastatic | adult patients with unresectable hepatocellular carcinoma | adult patients with unresectable hepatocellular carcinoma | adult patients with primary advanced or recurrent endometrial cancer | adult patients with primary advanced or recurrent endometrial cancer | adult patients with muscle invasive bladder cancer | the treatment of adult patients with unresectable Stage III NSCLC whose disease | the treatment of adult patients with metastatic NSCLC who have disease | the treatment of adult patients with locally advanced or metastatic biliary tract cancer | the treatment of adult patients with locally advanced or metastatic | the treatment of adult patients with unresectable hepatocellular carcinoma | the treatment of adult patients with unresectable hepatocellular carcinoma | the treatment of adult patients with primary advanced or recurrent endometrial cancer | the treatment of adult patients with primary advanced or recurrent endometrial cancer | the treatment of adult patients with muscle invasive bladder cancer | for the treatment of adult patients with unresectable Stage III NSCLC whose disease | for the treatment of adult patients with metastatic NSCLC who have disease | for the treatment of adult patients with locally advanced or metastatic biliary tract cancer | for the treatment of adult patients with locally advanced or metastatic | for the treatment of adult patients with unresectable hepatocellular carcinoma | for the treatment of adult patients with unresectable hepatocellular carcinoma | for the treatment of adult patients with primary advanced or recurrent endometrial cancer | for the treatment of adult patients with primary advanced or recurrent endometrial cancer | for the treatment of adult patients with muscle invasive bladder cancer,"A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-Center, International Study of Durvalumab Given Concurrently With Definitive Chemoradiation Therapy in Patients With Locally Advanced, Unresectable Esophageal Squamous Cell Carcinoma (KUNLUN) | Unknown | Recruiting | NCT04550260 || Brachytherapy With Durvalumab (MEDI4736) and Tremelimumab in Subjects With Platinum-Resistant or Refractory and Recurrent or Metastatic Gynecological Malignancies | Unknown | Recruiting | NCT04395079 || A Phase IIIb Study of Durvalumab as Consolidation Treatment for Patients Diagnosed With Limited Stage Small Cell Lung Cancer Who Have Not Progressed Following Definitive Concurrent or Sequential Platinum-based Chemoradiation Therapy in Spain (ALBORAN). | Unknown | Recruiting | NCT06992609 || A Phase II Study of Neoadjuvant Chemotherapy Plus Durvalumab (MEDI4736) and Tremelimumab in Advanced-stage Ovarian Cancer (TRU-D) | Unknown | Unknown | NCT03899610 || A Pilot Study of Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers | Unknown | Recruiting | NCT06564623 || Phase Ib/II Study of Concurrent Durvalumab And Radiation Therapy (DUART) Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder: Big Ten Cancer Research Consortium BTCRC-GU15-023 | Unknown | Terminated | NCT02891161 || Randomized Phase I/II Study of Ablative Radiotherapy +/- MEDI 4736 (Durvalumab) for Medically Inoperable Early-Stage Non-Small Cell Lung Cancer | Unknown | Recruiting | NCT03148327 || Durvalumab and Standard Chemotherapy for the Treatment of Lymph Node Positive Bladder Cancer | Unknown | Recruiting | NCT05137262 || Durvalumab in Combination With Standard Chemotherapy for 1st Line Therapy of Patients With Extensive Stage Small Cell Lung Cancer: A Non-interventional, Prospective Observational Study of Clinical Practice, Quality of Life and Use of Health Resources in Real-world Clinical Practice (DRIVE) | Unknown | Unknown | NCT05761977 || Official Title: A Phase II Multicenter, Open Label, Non-randomized Study of Neoadjuvant and Adjuvant Treatment With IPH5201 and Durvalumab in Patients With Resectable, Early-stage (II to IIIA) Non-Small Cell Lung Cancer (MATISSE) | Unknown | Recruiting | NCT05742607 || Safety & Efficacy of Neoadjuvant Immunotherapy With Durvalumab (MEDI 4736) Combined With Neoadjuvant Chemotherapy (Gemcitabine/Cisplatin or Gemcitabine/Carboplatin) in Patients With Operable, High-risk, Localized Urothelial Carcinoma of the Upper Urinary Tract | Unknown | Recruiting | NCT04617756 || Randomized Phase II Study of Durvalumab and Tremelimumab Combination Versus Standard of Care Following First-line Platinum Based Chemotherapy in Two Cohorts of Patients With Non Squamous and Squamous Non-small-cell Lung Cancer (NSCLC) | Unknown | Withdrawn | NCT03319316 || Phase II Trial of Palliative Hypofractionated Radiotherapy Followed by Durvalumab (MEDI4736) With/Without Tremelimumab for Advanced Hepatocellular Carcinoma After Progression on Prior PD-1 Inhibition | Unknown | Recruiting | NCT04430452 || A Phase II Whole Exome Sequencing-based Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors | Unknown | Withdrawn | NCT03982173 || A Single-arm, Phase II Study of Durvalumab (MEDI4736) and Tremelimumab for Relapsed/Refractory Germ Cell Tumors | Unknown | Recruiting | NCT03158064 || Phase II Trial of Durvalumab (MEDI4736 )/Tremelimumab Combined With Definitive Concurrent Chemo-radiotherapy for Inoperable Esophageal Squamous Cell Carcinoma | Unknown | Unknown | NCT03377400 || Phase I/II, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Durvalumab Monotherapy or in Combination With Tremelimumab in Pediatric Patients With Advanced Solid Tumors and Hematological Malignancies. | Unknown | Recruiting | NCT03837899 || Biomarker-oriented Study of Durvalumab(MEDI4736)/Tremelimumab in Combination With Gemcitabine/Cisplatin in Chemotherapy-naïve Biliary Tract Cancer | Unknown | Recruiting | NCT03046862 || A Multicentre Feasibility Randomized Study of Anti-PD-L1 Durvalumab (MEDI4736) With or Without Anti-CTLA-4 Tremelimumab in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma, Treated With a First-line Neo-adjuvant Strategy | Unknown | Recruiting | NCT03249142"
AstraZeneca Pharmaceuticals LP,OSIMERTINIB,TAGRISSO,Y,2024-09-25,Kinase Inhibitor,EGFR | MET | ATM | ATR,Kinase Inhibitor,based chemoradiation therapy and whose tumor | adult patients with unresectable Stage III NSCLC whose disease | adult patients with locally advanced or metastatic | adult patients with unresectable Stage III NSCLC whose disease | adult patients with metastatic NSCLC who have disease | adult patients with metastatic NSCLC whose tumor | adult patients with locally advanced or metastatic NSCLC whose tumor | stage small cell lung cancer | TAGRISSO is indicated as adjuvant therapy after tumor | Positive Non-Small Cell | line treatment of adult patients with metastatic NSCLC whose tumor | positive metastatic | line treatment of adult patients with metastatic non-small cell | line treatment of adult patients with locally advanced or metastatic NSCLC whose tumor | Positive Locally Advanced or Metastatic | positive NSCLC who had complete tumor | the treatment of adult patients with locally advanced or metastatic | the treatment of adult patients with metastatic NSCLC who have disease | as adjuvant therapy after tumor resection in adult patients with non-small cell | for the treatment of adult patients with locally advanced or metastatic | for the treatment of adult patients with metastatic NSCLC who have disease,"A Biomarker-directed Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy. | Phase 2 | Recruiting | NCT03944772 || Phase 3, Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Combined With Osimertinib vs Platinum-Based Chemotherapy in Subjects With c-Met Overexpressing (OE) EGFR Mutant, Locally Advanced/Metastatic Non-Squamous NSCLC After a First Progression on Prior Third Generation EGFR TKi Treatment | Unknown | Withdrawn | NCT06093503 || A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Neoadjuvant Osimertinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harbouring EGFR Mutations | Unknown | Recruiting | NCT04816838 || An Open-label, Single-arm, Phase II Trial of Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After a Double Dose of Third-generation TKIs, Including Osimertinib | Unknown | Recruiting | NCT06296745 || Evaluate the Safety and Efficacy of Almonertinib in the Treatment of Advanced NSCLC Patients With EGFR-sensitive Mutations Who Are Safety Intolerant After Osimertinib Treatment: a Prospective, Multi-center, Single-arm Clinical Trial | Unknown | Unknown | NCT04882345 || A Phase II Trial of Osimertinib and Abemaciclib With a Focus on Non-Small Cell Lung Cancer Patients With EGFR Activating Mutations With Osimertinib Resistance | Unknown | Recruiting | NCT04545710 || A Phase II, Two-arm Study to Investigate Tepotinib Combined With Osimertinib in MET Amplified, Advanced or Metastatic NSCLC Harboring Activating EGFR Mutations and Having Acquired Resistance to Prior Osimertinib Therapy (INSIGHT 2) | Unknown | Recruiting | NCT03940703 || A Phase I Trial of Osimertinib (AZD9291) and Necitumumab in EGFR-Mutant Non-Small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase Inhibitor | Unknown | Recruiting | NCT02496663 || A Prospective, Multi-center, Interventional Study of Osimertinib Combined With Anlotinib in Acquired EGFR T790M Mutated NSCLC Patients With Gradual Progression on Osimertinib Treatment | Unknown | Terminated | NCT04438902 || A Multicentre Single-arm Phase II Trial Assessing the Safety and Efficacy of First-line Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer | Unknown | Terminated | NCT04908956 || A Phase Ib,Open Label,Multi-center Study to Assess the Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations | Unknown | Unknown | NCT04448379 || A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure | Unknown | Recruiting | NCT04988295"
AstraZeneca Pharmaceuticals LP,OLAPARIB,Lynparza,Y,2025-07-10,Chemotherapy,PARP,,negative metastatic breast cancer | negative metastatic breast cancer | negative metastatic breast cancer | adult patients with unresectable or metastatic hepatocellular carcinoma | resistant prostate cancer | resistant prostate cancer | mutated metastatic | adjuvant or metastatic | therapy or chemotherapy for metastatic disease | fallopian tube or primary peritoneal cancer | mutated advanced | based chemotherapy and whose cancer | adult patients with advanced | negative high risk early breast cancer | negative high risk early breast cancer | metastatic pancreatic adenocarcinoma whose disease | mutated Advanced Ovarian Cancer | positive Advanced Ovarian Cancer | mutated Recurrent Ovarian Cancer | in combination with bevacizumab for the maintenance treatment of adult patients with advanced,"MITO 35a: A Multicenter, Prospective, Single Arm Trial of Olaparib Maintenance Therapy in Newly Diagnosed BRCA Wildtype Advanced Ovarian, Fallopian Tube and Primitive Peritoneal Cancer | Unknown | Recruiting | NCT05233982 || A Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab With or Without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) | Unknown | Recruiting | NCT03976362 || Focal Radiation With Pulsed Systemic Therapy of Abiraterone, ADT, Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON): A Phase II, Single Arm, Single Institution Study | Unknown | Recruiting | NCT04748042 || A Phase II Study of the PARP Inhibitor Olaparib (AZD2281) Alone and in Combination With AZD1775, AZD5363, or AZD6738 in Advanced Solid Tumors | Unknown | Terminated | NCT02576444 || A Phase II Study in Newly Diagnosed Stage III/IV Epithelial Ovarian Cancer Evaluating Carbo/Taxol/Pembro in Patients Receiving Neoadjuvant Chemotherapy (NACT) Followed by Olaparib/Pembro Maintenance | Unknown | Recruiting | NCT05952453 || Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian | Unknown | Unknown | NCT02822157 || Pembrolizumab and Olaparib in Recurrent/Metastatic, Platinum Resistant Nasopharyngeal Cancer | Unknown | Recruiting | NCT04825990 || A Single-arm Phase II Study of Olaparib Maintenance With Pembrolizumab & Bevacizumab in BRCA Non-mutated Patients With Platinum-sensitive Recurrent Ovarian Cancer (OPEB-01) | Unknown | Unknown | NCT04361370 || Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas | Unknown | Recruiting | NCT03259503 || A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma | Unknown | Recruiting | NCT04394858 || Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients. The Phase III Randomized, Open Label MITO 35b Study: a Project of the MITO-MANGO Groups. | Unknown | Recruiting | NCT05255471 || Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma | Unknown | Recruiting | NCT06160843"
AstraZeneca Pharmaceuticals LP,TREMELIMUMAB,IMJUDO,Y,2024-07-24,Monoclonal Antibody,PD-1 | PD-L1 | CTLA-4 | EGFR | ALK | MET | RET | ERK | ATM | ATR,Monoclonal Antibody,adult patients with unresectable hepatocellular carcinoma | adult patients with unresectable hepatocellular carcinoma | mutations or anaplastic lymphoma | with no EGFR or ALK genomic tumor | adult patients with metastatic NSCLC who have disease | stage small cell lung cancer | mutation or anaplastic lymphoma | adult patients with metastatic non-small cell | the treatment of adult patients with unresectable hepatocellular carcinoma | the treatment of adult patients with unresectable hepatocellular carcinoma | the treatment of adult patients with metastatic NSCLC who have disease | for the treatment of adult patients with unresectable hepatocellular carcinoma | for the treatment of adult patients with unresectable hepatocellular carcinoma | for the treatment of adult patients with metastatic NSCLC who have disease,Phase II Single Arm Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas with Child-Pugh-B Cirrhosis (STRIDE in CP-B) | Unknown | Recruiting | NCT06526104
"Teva Pharmaceuticals, Inc.",GEFITINIB,Gefitinib,Y,2022-02-28,Kinase Inhibitor,EGFR | MET | ATM,Kinase Inhibitor,stage small cell lung cancer | adult patients with metastatic NSCLC whose tumor | stage small cell lung cancer | adult patients with metastatic non-small cell | adult patients with metastatic NSCLC who have disease | line treatment of patients with metastatic non-small cell | line treatment of patients with metastatic colorectal cancer,"A Multi-arm, Phase Ib, Open-Label, Multicentre Study to Assess the Safety,Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9291 in Combination With Ascending Doses of Novel Therapeutics in Patients With EGFRm+ Advanced NSCLC Who Have Progressed Following Therapy With an EGFR TKI (TATTON). | Unknown | Recruiting | NCT02143466 || Evaluation of the Efficacy of Domestic Gefitinib Tablets in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients Using a Multicenter, Randomized, Positive Drug Gefitinib Pharmacodynamics and Pharmacodynamics | Unknown | Unknown | NCT03264794 || A Randomized Phase III Study of Follow Up With or Without Adjuvant Gefitinib (Iressa™) Following Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer | Unknown | Terminated | NCT00091156 || Recombinant Anti-VEGFR2 Fully Human Monoclonal Antibody (JY025) Injection Combined With Gefitinib/Erlotinib as First-line Treatment Phase II and III Clinical Trials on the Efficacy and Safety of Patients With EGFR-mutant NSCLC | Unknown | Unknown | NCT04874844 || A Randomized, Open-label, Phase III Study of Single Agent Nazartinib Versus Investigator's Choice (Erlotinib or Gefitinib) as First-Line Treatment in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Activating Mutations | Unknown | Withdrawn | NCT03529084"
Amgen,BLINATUMOMAB,BLINCYTO,Y,2025-04-29,Vaccine,CD19 | CD3,,cell precursor acute lymphoblastic leukemia | in first or second complete remission with minimal residual disease | positive B-cell | adult patients with relapsed or refractory follicular lymphoma | negative B-cell | the treatment of relapsed or refractory | for the treatment of relapsed or refractory,"A Pilot Study of Blinatumomab in Combination With a PD1 Inhibitor, Pembrolizumab, in Pediatric and Young Adult Patients With Relapsed/Refractory CD19 Positive B-cell Acute Leukemia or Lymphoma | Unknown | Withdrawn | NCT03605589 || Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL) | Unknown | Recruiting | NCT02101853 || A Prospective, Single-arm Clinical Study of Blinatumomab in the Maintenance Treatment of High-risk Patients With Acute B-lymphoblastic Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation | Unknown | Recruiting | NCT06658938 || Study of Blinatumomab for the Treatment of Calcineurin Inhibitor-Resistant or Intolerant Steriod-Resistant Nephrotic Syndrome in Pediatric Patients | Unknown | Recruiting | NCT06607991 || Blinatumomab for Minimal Residual Disease Before Hematopoietic Stem Cell Transplantation With Pediatric B-cell Precursor Acute Lymphoblastic Leukemia | Unknown | Unknown | NCT04604691 || Efficacy Study of Blinatumomab Clean Up Early Residual Disease for Newly Diagnosed Pediatric B Lymphoblastic Leukemia | Unknown | Recruiting | NCT06607419 || A Phase II, Open-label Study to Evaluate the Effect of Blinatumomab Administered During Consolidation to Reduce the Level of Minimal Residual Disease (MRD) Assessed Through Flow Cytometry in Adult Patients up to 55 Years of Age With High-risk Philadelphia Chromosome-negative (Ph-) Acute Lymphoblastic Leukaemia (ALL) With Good Response (MRD < 0.1%) After Induction Therapy | Unknown | Terminated | NCT03523429 || Phase II Study of Blinatumomab in Patients With B-Cell Lineage Acute Lymphocytic Leukemia With Positive Minimal Residual Disease | Unknown | Recruiting | NCT02458014 || A Multicenter, Prospective Clinical Study of Olverembatinib Combined With Blinatumomab in the Treatment of Adult de Novo Philadelphia Chromosome Positive Acute Lymphoid Leukemia | Unknown | Recruiting | NCT05931757 || An Open-Label, Multi-center, Expanded Access Protocol of Blinatumomab for the Treatment of Pediatric and Adolescent Subjects With Relapsed and/or Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) | Unknown | Unknown | NCT02187354 || Immune Reconstitution After Allogeneic Hematopoietic Stem Cell Transplantation With Post-transplant Blinatumomab Maintenance Treatment | Unknown | Recruiting | NCT06075212 || A Phase 1/2 Open-label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) and Minimal Residual Disease Positive (MRD+) B-ALL | Phase 1 | Recruiting | NCT04521231 || Efficacy and Safety of Blinatumomab Maintenanceafter Allogeneic Hematopoietic Stem Cell Transplantation for High-risk Acute B-lymphoblastic Leukemia: a Multicenter, Open-label, Randomized Controlled Study | Unknown | Recruiting | NCT06438796"
Amgen,TARLATAMAB,IMDELLTRA,Y,2024-05-16,Chemotherapy,ALK | MET | ATM | ATR | DLL3,,adult patients with extensive stage small cell lung cancer | with disease | the treatment of adult patients with extensive stage small cell lung cancer | the treatment of adult patients with extensive stage small cell lung cancer | the treatment of adult patients with extensive stage small cell lung cancer | for the treatment of adult patients with extensive stage small cell lung cancer | for the treatment of adult patients with extensive stage small cell lung cancer | for the treatment of adult patients with extensive stage small cell lung cancer,
Amgen,SOTORASIB,LUMAKRAS,Y,2025-01-22,Chemotherapy,ALK | MET | ATM | KRAS,,stage small cell lung cancer | stage small cell lung cancer | mutated locally advanced or metastatic non-small cell | mutated locally advanced or metastatic non-small cell | mutated metastatic colorectal cancer | mutated metastatic colorectal cancer | mutated metastatic,"A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients With Previously Treated KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer | Unknown | Recruiting | NCT06497556 || A Phase I Clinical Trial of Carfilzomib in Combination With Sotorasib in Patients With KRASG12C Mutated Advanced Non-Small Cell Lung Cancer | Unknown | Recruiting | NCT06249282 || A Phase 1/2 Study of Avutometinib (VS-6766) in Combination With Sotorasib With or Without Defactinib in Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC) | Phase 1 | Recruiting | NCT05074810 || A Multicentre, Single-arm Phase II Trial of Sotorasib Plus Lenvatinib, As Second-line Treatment in Patients with KRASG12C-mutant, Metastatic NSCLC | Unknown | Withdrawn | NCT06068153 || Real World Evaluation of Sotorasib Among Chinese Non-Small Cell Lung Cancer Patients | Unknown | Recruiting | NCT07143513 || Assessment and Follow-up of Patients With KRAS G12C-mutated Metastatic Non-Small Cell Lung Cancer Who Received Sotorasib as Part of the French Early Access Program (ATU) | Unknown | Recruiting | NCT05273047 || Neoadjuvant Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA Non-Small Cell Lung Cancer (NSCLC) | Unknown | Withdrawn | NCT05400577 || Sotorasib Combined With First-line Chemotherapy for Advanced Pancreatic Adenocarcinoma With KRAS p.G12C Mutation | Unknown | Recruiting | NCT06892054 || A Randomized Phase II Study of AMG 510 (Sotorasib) With or Without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment Trial | Unknown | Recruiting | NCT05638295 || A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation | Unknown | Recruiting | NCT05118854 || Phase II Study of Ladarixin and Sotorasib In Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC) | Unknown | Withdrawn | NCT05815186"
"Onyx Pharmaceuticals, Inc.",CARFILZOMIB,KYPROLIS,Y,2025-06-18,Prescription Drug,MET | RET | ERK | ATM | ATR | PROTEASOME | PROTEASOME INHIBITOR,,adult patients with relapsed or refractory follicular lymphoma | adult patients with relapsed or refractory follicular lymphoma | the treatment of adult patients with relapsed or refractory follicular lymphoma | for the treatment of adult patients with relapsed or refractory follicular lymphoma | single agent for the treatment of adult patients with relapsed or refractory,"Clinical Phase II, Multicenter, Open-label Study Evaluating iNduction, Consolidation and Maintenance With Isatuximab (SAR650984), Carfilzomib, LEnalidomide and Dexamethasone (I-KRd) in Primary Diagnosed High-risk Multiple Myeloma paTients | Unknown | Recruiting | NCT03104842 || A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-2 | Unknown | Recruiting | NCT05552976 || Single Arm, Multicentre Study of Carfilzomib in Combination With Thalidomide and Dexamethasone (CaTD) in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) | Unknown | Unknown | NCT03140943 || Phase I/II Study of Carfilzomib in Combination With Bendamustine and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma | Unknown | Terminated | NCT02002598 || Phase II, Single-arm Trial of Carfilzomib, Pomalidomide, and Dexamethasone for Myeloma Patients Who Had Relapsed or Progressed After Carfilzomib, Lenalidomide, and Dexamethasone | Unknown | Unknown | NCT05509374"
SEAGEN INC.,ENFORTUMAB VEDOTIN,PADCEV,Y,2025-02-28,Chemotherapy,PD-1 | PD-L1 | MET | RET | ATM | PROGRAMMED DEATH,,adult patients with locally advanced or metastatic urothelial cancer | adult patients with locally advanced or metastatic | adult patients with locally advanced or metastatic | the treatment of adult patients with locally advanced or metastatic urothelial cancer | the treatment of adult patients with locally advanced or metastatic | the treatment of adult patients with locally advanced or metastatic | for the treatment of adult patients with locally advanced or metastatic urothelial cancer | for the treatment of adult patients with locally advanced or metastatic | for the treatment of adult patients with locally advanced or metastatic,"Phase II Study of Enfortumab Vedotin Treatment for Metastatic Squamous Cell Carcinoma of the Penis | Unknown | Recruiting | NCT06104618 || A Phase 1/2 Randomized, Umbrella Study to Evaluate the Safety and Efficacy of Pembrolizumab Plus Enfortumab Vedotin (EV) in Combination With Investigational Agents Versus Pembrolizumab Plus EV, as First-Line Treatment for Participants With Advanced Urothelial Carcinoma (KEYMAKER-U04): Substudy 04B | Phase 1 | Recruiting | NCT05845814 || Renal Retention in High Grade Upper Tract Urothelial Cancer: A Phase II Trial of Enfortumab Vedotin and Pembrolizumab in Patients With Upper Tract Urothelial Cancer (UTUC) Who Are Not Candidates for, or Refuse, Nephroureterectomy | Unknown | Recruiting | NCT05656235 || Activity of Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma | Unknown | Recruiting | NCT06302569 || Biomarker Studies to Predict Treatment Outcomes of Enfortumab Vedotin in Advanced Urothelial Carcinoma | Unknown | Recruiting | NCT07063758 || A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants With Muscle-invasive Bladder Cancer (KEYNOTE-B15 / EV-304) | Unknown | Recruiting | NCT04700124 || Neoadjuvant Enfortumab Vedotin in High-Grade Urothelial Carcinoma of the Upper Urinary Tract (Including Ureter and Renal Pelvis) | Unknown | Recruiting | NCT05868265 || An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | Phase 2 | Recruiting | NCT04225117 || A Prospective Study Assessing Neurological Function and Its Clinical Implications in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Receiving Enfortumab Vedotin-Based Therapy | Unknown | Recruiting | NCT07072637 || Neoadjuvant Combination Pembrolizumab / Enfortumab Vedotin With Adjuvant Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Carcinoma | Unknown | Recruiting | NCT05775471 || Enfortumab Vedotin in Combination with Pembrolizumab for Locally Advanced And/or Node Positive Urothelial Carcinoma Prior to Surgery (EV-ECLIPSE) | Unknown | Recruiting | NCT05239624 || A Multicenter, Open-label, Expanded Access Treatment Protocol of Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Urothelial Carcinoma (EV-901) | Unknown | Unknown | NCT04136808 || A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC) | Unknown | Recruiting | NCT05014139 || DEPECA-1 - DEfeating PEnile Cancer 1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma | Unknown | Recruiting | NCT07110038 || A Randomized, Open-Label, Phase 2/3 Study of Datopotamab Deruxtecan (Dato-DXd) Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) Who Progressed During or After Enfortumab Vedotin (EV) Plus Pembrolizumab Combination Treatment TROPION-Urothelial03 (TU03) | Phase 2 | Recruiting | NCT07129993 || Phase II Trial of Enfortumab Vedotin in Recurrent and/or Metastatic Adenoid Cystic Carcinoma | Unknown | Recruiting | NCT06891560 || A Pilot Trial of Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma | Unknown | Recruiting | NCT05923190"
"Astellas Pharma US, Inc.",GILTERITINIB,Xospata,Y,2022-01-01,Kinase Inhibitor,ALK | MET | FLT3 | ERK | ATM,Kinase Inhibitor,adult patients who have relapsed or refractory acute myeloid leukemia | adult patients who have relapsed or refractory acute myeloid leukemia | the treatment of adult patients who have relapsed or refractory acute myeloid leukemia | the treatment of adult patients who have relapsed or refractory acute myeloid leukemia | for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia | for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia,"Observational Study on the Incidence of Infections in Patients With Relapsed/Refractory FMS-like Tyrosine Kinase 3 Acute Myeloid Leukemia Treated With Gilteritinib | Unknown | Unknown | NCT05791890 || A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations | Unknown | Recruiting | NCT04293562 || AGORA-1 /ALFA 2100 Study : a Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults with FLT3-ITD Relapse/refractory (R/R) AML | Phase 2 | Recruiting | NCT05199051 || A Phase 1b Multi-center Study of the FLT3 Inhibitor Gilteritinib in Combination With the IDH1 Inhibitor Ivosidenib or the IDH2 Inhibitor Enasidenib for Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Have Co-occurring FLT3/IDH1 or FLT3/IDH2 Mutations | Phase 1 | Recruiting | NCT05756777 || A Multicenter, Open-label Treatment Protocol of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD) | Unknown | Unknown | NCT03070093 || Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML) | Unknown | Recruiting | NCT03836209 || A Phase 2, Open-label, Multicentre Study Investigating Tolerability and Efficacy of Gilteritinib in Combination With Fludarabine, Cytarabine and Idarubicin (FLAI) as Induction Therapy of Newly Diagnosed Non-M3 FLT3-positive Acute Myeloid Leukemia | Phase 2 | Recruiting | NCT06667973 || A Phase 1/2, Multicenter, Open-Label, Single Arm, Dose Escalation and Expansion Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) | Phase 1 | Terminated | NCT04240002"
"Astellas Pharma US, Inc.",ZOLBETUXIMAB,VYLOY,Y,2025-06-12,Chemotherapy,HER2 | ALK | MET | RET | ATM | CLAUDIN 18.2 | HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR,,adenocarcinoma whose tumor | negative gastric | adults with locally advanced unresectable or metastatic | negative gastric or gastroesophageal junction adenocarcinoma whose tumor | line treatment of adults with locally advanced unresectable or metastatic,"A Phase 1 Open-label Study to Assess the Safety and Tolerability of Zolbetuximab (IMAB362) in Combination With Chemotherapy (mFOLFIRINOX) in Participants With CLDN18.2 Positive Metastatic Pancreatic Adenocarcinoma | Phase 1 | Recruiting | NCT06396091 || A Global, Multicenter, Open-label, Early Access Program for Zolbetuximab (IMAB362) Plus mFOLFOX6 or CAPOX in Patients With Claudin18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | Unknown | Unknown | NCT06048081 || A Phase 3, Double-blind, Randomized Study of Zolbetuximab in Combination With Pembrolizumab and Chemotherapy (CAPOX or mFOLFOX6) in First-line Treatment of Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma in Participants Whose Tumors Are HER2-negative, Claudin (CLDN) 18.2-positive and Programmed Death-ligand 1 (PD-L1)-Positive | Unknown | Recruiting | NCT06901531 || Phase II RAINSPOT: a Multicentric Open Label Trial of Zolbetuximab-Paclitaxel-Ramucirumab in Second Line Setting for CLDN18.2 Positive Gastro-esophageal Adenocarcinoma | Unknown | Recruiting | NCT06962137 || Post-marketing Observational Study of VYLOY (Zolbetuximab) Injection 100 mg for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma in South Korea | Unknown | Recruiting | NCT06902545 || A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus mFOLFOX6 Compared With Placebo Plus mFOLFOX6 as First-line Treatment of Subjects With Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | Unknown | Recruiting | NCT03504397 || A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy and in Combination With Chemotherapy and/or Immunotherapy in Subjects With Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and Locoregional Gastric or GEJ Adenocarcinoma Whose Are Claudin (CLDN) 18.2 Positive | Phase 2 | Recruiting | NCT03505320 || Multi-center Cohort Study to Evaluate the Real-world Efficacy and Safety of Zolbetuximab Plus Chemotherapy in Claudin18.2 Positive, HER2 Negative, Advanced Gastric Cancer | Unknown | Recruiting | NCT06767449 || A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | Unknown | Recruiting | NCT03653507 || A Phase 2, Open-Label, Randomized Study to Assess the Efficacy and Safety of Zolbetuximab (IMAB362) in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma | Phase 2 | Recruiting | NCT03816163 || A Phase Ib/II Trial of Neoadjuvant Zolbetuximab Plus Docetaxel, Oxaliplatin and S-1 Chemotherapy in Patients With Locally Advanced Gastric Cancer | Unknown | Recruiting | NCT06732856"
"Astellas Pharma US, Inc.",FEZOLINETANT,VEOZAH,Y,2024-12-27,,ALK | RET | ATM,,moderate to severe vasomotor symptoms due to menopause,"A Phase 3, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of Fezolinetant in Japanese Women Experiencing Vasomotor Symptoms (Hot Flashes) Associated With Menopause | Unknown | Recruiting | NCT06206408 || Efficacy and Safety of Fezolinetant for Treatment of Moderate to Severe Vasomotor Symptoms Associated With Androgen-Deprivation Therapy in Men With Prostate Cancer (FLASH): A Phase 2 Study | Phase 2 | Recruiting | NCT06972875 || A Phase 2, Randomized, Placebo-controlled, 12-week, Double-blind Study to Assess the Efficacy and Safety of Fezolinetant 45 mg in Chinese Women Suffering From Moderate to Severe Vasomotor Symptoms (Hot Flashes) Associated With Menopause | Phase 2 | Recruiting | NCT06812754 || A Phase 3, Randomized, Placebo-controlled, Double-blind Study to Investigate the Long Term Safety of Fezolinetant in Japanese Women Suffering From Vasomotor Symptoms (Hot Flashes) Associated With Menopause | Unknown | Recruiting | NCT06206421 || A Randomized, Placebo-controlled, Double-blind, Phase 3 Clinical Study to Investigate the Efficacy and Safety of Fezolinetant for Treatment of Moderate to Severe Vasomotor Symptoms (Hot Flashes) in Women With Stage 0 to 3 Hormone Receptor-positive Breast Cancer Who Are Receiving Adjuvant Endocrine Therapy | Unknown | Recruiting | NCT06440967 || A Randomized Phase II Study to Evaluate the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy | Unknown | Recruiting | NCT06917313 || Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy (Fezo-ADT Trial) | Unknown | Recruiting | NCT06957691"
Bayer HealthCare Pharmaceuticals Inc.,DAROLUTAMIDE,NUBEQA,Y,2025-06-11,Prescription Drug,MET | RET | ATM,,resistant prostate cancer | resistant prostate cancer | metastatic castration resistant prostate cancer | sensitive prostate cancer | sensitive prostate cancer,"Post-marketing Surveillance Study for Approved Darolutamide Use in Korean Patients | Unknown | Recruiting | NCT06334120 || A Randomized Phase II Trial of Docetaxel or Cabazitaxel With or Without Darolutamide in Men With Metastatic Castration-resistant Prostate Cancer | Unknown | Recruiting | NCT05762536 || A Phase II Neoadjuvant Clinical Trial of the Androgen Receptor Inhibitor Darolutamide in Early-Stage Androgen Receptor Positive (AR+) Triple-Negative Breast Cancer | Unknown | Recruiting | NCT07016399 || A Phase II, Multi-center, Single-arm, Prospective Study of Darolutamide + ADT Prior to Radical Prostatectomy (RP) in High-risk/Very High-risk Localized Prostate Cancer | Unknown | Recruiting | NCT06029036 || Comeback From Long coursE ADT With RElugolix and Darolutamide in Hormone-sensitive Prostate Cancer (CLEARED) | Unknown | Recruiting | NCT06463457 || A Randomised, Phase 3 Trial Comparing 3-weekly Docetaxel 75 mg/m2 (in a 3 Week Cycle) Versus 2-weekly Docetaxel 50 mg/m2 (in a 4 Week Cycle) in Combination With Darolutamide + ADT in Patients With mHSPC | Unknown | Recruiting | NCT05676203 || Stereotactic Body Radiotherapy With or Without Darolutamide for OligoRecurrent Prostate Cancer: a Randomized Phase II Trial (DART) | Unknown | Recruiting | NCT04641078 || An Observational Study of Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients With Low-volume Metastatic Hormone-sensitive Prostate Cancer | Unknown | Recruiting | NCT06661122 || A Phase III Randomized Study Comparing the Combination of Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With Metastatic Castration-Sensitive Prostrate Cancer (mCSPC) | Unknown | Withdrawn | NCT05771896 || A Phase 1/2 Study of Darolutamide and Abemaciclib in High-Risk Prostate Cancer | Phase 1 | Recruiting | NCT05617885 || A Phase 2 Randomized Open-Label Study of Oral Darolutamide (ODM-201) vs. Androgen Deprivation Therapy (ADT) With LHRH Agonists or Antagonist in Men With Hormone Naive Prostate Cancer | Phase 2 | Recruiting | NCT02972060 || A Randomized Trial of Neoadjuvant Leuprorelin, Darolutamide or Both Prior to Radical Prostatectomy for Intermediate or High-risk Prostate Cancer | Unknown | Recruiting | NCT06627530"
Merck & Co.,Pembrolizumab,KEYTRUDA,Y,2025-08-19,Monoclonal Antibody,PD-1 | PD-1,Monoclonal Antibody,adult patients with unresectable or metastatic melanoma | adult patients with unresectable or metastatic hepatocellular carcinoma | adult patients with metastatic NSCLC whose tumor | adult patients with metastatic NSCLC who have disease | adult patients with resectable locally advanced HNSCC whose tumor | adult patients with resectable locally advanced HNSCC whose tumor | patients with recurrent or metastatic HNSCC with disease | patients with recurrent or metastatic HNSCC with disease | adult patients with relapsed or refractory classical Hodgkin lymphoma | adult patients with relapsed or refractory follicular lymphoma | pediatric patients with refractory | cell lymphoma | adult and pediatric patients with refractory primary mediastinal large B-cell | adult and pediatric patients with refractory primary mediastinal large B-cell | adult patients with locally advanced or metastatic urothelial cancer | adult patients with locally advanced or metastatic | patients with locally advanced or metastatic urothelial carcinoma | or who have disease | adult patients with muscle invasive bladder cancer | with carcinoma | with or without papillary tumor | month of age with solid tumor | adult and pediatric patients with unresectable or metastatic | or dMMR colorectal cancer | or dMMR colorectal cancer | based chemotherapy for patients with tumor | patients with locally advanced cervical cancer | or metastatic cervical cancer whose tumor | patients with recurrent or metastatic cervical cancer with disease | patients with hepatocellular carcinoma | patients with hepatocellular carcinoma | patients with locally advanced unresectable or metastatic biliary tract cancer | patients with locally advanced unresectable or metastatic biliary tract cancer | adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma | adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma | adult patients with primary advanced or recurrent endometrial carcinoma | adult patients with primary advanced or recurrent endometrial cancer | adult patients with advanced endometrial carcinoma | adult patients with advanced | adult and pediatric patients with unresectable or metastatic tumor | patients with recurrent or metastatic cutaneous squamous cell carcinoma | patients with recurrent or metastatic cutaneous squamous cell carcinoma | or locally advanced | negative breast cancer | negative breast cancer | patients with locally recurrent unresectable or metastatic TNBC whose tumor | patients with locally recurrent unresectable or metastatic TNBC whose tumor | with disease | based chemotherapy for patients whose tumor | single agent after one or more prior lines of systemic therapy for patients with tumor | patients with recurrent or metastatic cSCC or locally advanced | patients with locally advanced or metastatic urothelial carcinoma with disease | or dMMR Endometrial Carcinoma | or III melanoma | with no EGFR or ALK genomic tumor | adult patients with unresectable advanced or metastatic | recurrent HNSCC whose tumor | adenocarcinoma whose tumor | positive gastric | adults with locally advanced unresectable or metastatic | negative gastric | or following nephrectomy and resection of metastatic | stage small cell lung cancer | stage small cell lung cancer | patients with metastatic nonsquamous non-small cell | recurrent head and neck squamous cell carcinoma | adult patients with advanced renal cell carcinoma | Resected Stage IIB or IIC Melanoma | patients with Stage IIB or IIC melanoma | Stage III Resected Melanoma | IIIB or IIIC melanoma | metastatic nonsquamous NSCLC with no EGFR or ALK genomic tumor | locally advanced or metastatic breast cancer | controlled trial in patients with resectable locally advanced | recurrent or metastatic | positive gastric or GEJ cancer | negative gastric or GEJ cancer | Locally Advanced Unresectable or Metastatic Esophageal Cancer | line treatment in patients with metastatic or locally advanced | the treatment of patients with unresectable or metastatic melanoma | the treatment of patients with unresectable or metastatic melanoma | line treatment of patients with metastatic nonsquamous non-small cell | line treatment of patients with metastatic colorectal cancer | the treatment of patients with metastatic NSCLC whose tumor | the treatment of patients with metastatic NSCLC whose tumor | line treatment of adult patients with unresectable advanced or metastatic | the treatment of adult patients with resectable locally advanced HNSCC whose tumor | the treatment of adult patients with resectable locally advanced HNSCC whose tumor | the treatment of patients with recurrent or metastatic HNSCC with disease | the treatment of patients with recurrent or metastatic HNSCC with disease | the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma | the treatment of adult patients with relapsed or refractory follicular lymphoma | the treatment of pediatric patients with refractory | the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell | the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell | the treatment of adult patients with locally advanced or metastatic urothelial cancer | the treatment of adult patients with locally advanced or metastatic | the treatment of patients with locally advanced or metastatic urothelial carcinoma | the treatment of patients with locally advanced or metastatic urothelial carcinoma | the treatment of adult and pediatric patients with unresectable or metastatic | line treatment of adults with locally advanced unresectable or metastatic | the treatment of patients with locally advanced cervical cancer | the treatment of patients with recurrent or metastatic cervical cancer with disease | the treatment of patients with hepatocellular carcinoma | the treatment of patients with hepatocellular carcinoma | the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer | the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer | the treatment of adult and pediatric patients with recurrent locally advanced or metastatic | line treatment of adult patients with advanced renal cell carcinoma | line treatment of adult patients with advanced renal cell carcinoma | the treatment of adult patients with primary advanced or recurrent endometrial carcinoma | the treatment of adult patients with primary advanced or recurrent endometrial cancer | the treatment of adult patients with advanced endometrial carcinoma | the treatment of adult patients with advanced endometrial carcinoma | the treatment of adult and pediatric patients with unresectable or metastatic tumor | the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma | the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma | the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumor | the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumor | for the treatment of patients with unresectable or metastatic melanoma | for the treatment of patients with unresectable or metastatic melanoma | for the treatment of patients with metastatic NSCLC whose tumor | for the treatment of patients with metastatic NSCLC whose tumor | for the treatment of adult patients with resectable locally advanced HNSCC whose tumor | for the treatment of adult patients with resectable locally advanced HNSCC whose tumor | for the treatment of patients with recurrent or metastatic HNSCC with disease | for the treatment of patients with recurrent or metastatic HNSCC with disease | for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma | for the treatment of adult patients with relapsed or refractory follicular lymphoma | for the treatment of pediatric patients with refractory | for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell | for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell | for the treatment of adult patients with locally advanced or metastatic urothelial cancer | for the treatment of adult patients with locally advanced or metastatic | for the treatment of patients with locally advanced or metastatic urothelial carcinoma | for the treatment of patients with locally advanced or metastatic urothelial carcinoma | for the treatment of adult and pediatric patients with unresectable or metastatic | for the treatment of patients with locally advanced cervical cancer | for the treatment of patients with recurrent or metastatic cervical cancer with disease | for the treatment of patients with hepatocellular carcinoma | for the treatment of patients with hepatocellular carcinoma | for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer | for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer | for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic | for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma | for the treatment of adult patients with primary advanced or recurrent endometrial cancer | for the treatment of adult patients with advanced endometrial carcinoma | for the treatment of adult patients with advanced endometrial carcinoma | for the treatment of adult and pediatric patients with unresectable or metastatic tumor | for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma | for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma | for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumor | for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumor,"FDA Comprehensive Approval: PADCEV EJFV | Unknown | Unknown | NCT02091999 || FDA Comprehensive Approval: PADCEV EJFV | Unknown | Unknown | NCT03070990 || FDA Comprehensive Approval: PADCEV EJFV | Unknown | Unknown | NCT04995419 || A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Patients With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | Unknown | Recruiting | NCT06793215 || A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab Maintenance Following First-Line Platinum Based Chemotherapy in Patients With Metastatic Squamous - Non-Small Cell Lung Cancer (sNSCLC) | Unknown | Terminated | NCT02564380 || A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC) | Unknown | Recruiting | NCT05675579 || Efficacy and Safety Study of Acasunlimab as Monotherapy and in Combination With Pembrolizumab in Subjects With Relapsed/Refractory, Unresectable Locally Advanced or Metastatic Cutaneous Melanoma That Progressed On or After Treatment With a Checkpoint Inhibitor (ABBIL1TY MELANOMA-07) | Unknown | Recruiting | NCT06984328 || A Phase 2 Multi-Cohort, Open-Label Study of Intratumoral Tavokinogene Telseplasmid Plus Electroporation in Combination With Pembrolizumab +/- Chemotherapy in Patients With Inoperable Locally Advanced/Metastatic Triple-Negative Breast Cancer | Phase 2 | Unknown | NCT03567720 || SURE-02_An Open Label, Single-arm, Phase 2 Study of Perioperative Pembrolizumab Plus Sacituzumab Govitecan, and Bladder-saving Approach, for Patients With Muscle-invasive Bladder Cancer Who Cannot Receive or Refuse Cisplatin-based Chemotherapy | Phase 2 | Recruiting | NCT05535218 || A Single Arm, Multicenter, Phase 2 Trial to Evaluate the Efficacy of Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial) | Phase 2 | Terminated | NCT04267120 || A Feasibility Window Study of Pembrolizumab Prior to Second Evacuation for Post-molar Gestational Trophoblastic Neoplasia | Unknown | Recruiting | NCT05635344 || A Phase II, Open-label, Randomized, Multi-center Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal and Acral Melanoma Who Had Not Previously Received Systemic Therapy | Unknown | Recruiting | NCT06797297 || A Phase II Study of Pembrolizumab, Belantamab and Dexamethasone in Patients With Triple Class Refractory Multiple Myeloma. | Unknown | Withdrawn | NCT05493618 || Phase 1B, Pilot Study to Assess the Pharmacodynamics, Pharmacokinetics, Safety, Activity of Pembrolizumab Administered Intra-lymphatically Using the Sofusa® DoseConnect™ in Patients With Relapsed/Refractory Cutaneous T- Cell Lymphoma (CTCL) | Phase 1 | Unknown | NCT04118868 || A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy (MK-6482-022) | Unknown | Recruiting | NCT05239728 || An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or MK-1308A in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, as First-Line Treatment in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) | Unknown | Recruiting | NCT04736706 || An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or MK-1308A in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, as First-Line Treatment in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) | Unknown | Recruiting | NCT05899049 || An Open-Label, Phase 1 Study of MK-6482 as Monotherapy and in Combination With Lenvatinib (MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma | Phase 1 | Recruiting | NCT05030506 || Neoadjuvant Phase II Study of Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negative Breast Cancer (The TELESCOPE Study) | Unknown | Recruiting | NCT06604858 || A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) | Unknown | Recruiting | NCT06635824 || Multicentric Non-randomized Phase II of Pembrolizumab in Combination With Etoposide-cisplatin-based Chemotherapy in First-line Small Cell Ovarian Carcinoma of Hypercalcemic Type | Unknown | Recruiting | NCT04602377"
Merck & Co.,BELZUTIFAN,WELIREG,Y,2025-05-14,Kinase Inhibitor,PD-1 | PD-L1 | VEGF | ALK | MET | RET | ATM | ATR | VASCULAR ENDOTHELIAL GROWTH FACTOR | PROGRAMMED DEATH,Kinase Inhibitor,adult patients with advanced renal cell carcinoma | adult patients with advanced | years and older with locally advanced | adult patients with unresectable or metastatic hepatocellular carcinoma | disease who require therapy for associated renal cell carcinoma | or pancreatic neuroendocrine tumor | anemia in patients with VHL disease | the treatment of adult patients with advanced renal cell carcinoma | the treatment of adult patients with advanced endometrial carcinoma | for the treatment of adult patients with advanced renal cell carcinoma | for the treatment of adult patients with advanced endometrial carcinoma,"A Phase 1, Dose-escalation Study to Evaluate Safety and Tolerability of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) | Phase 1 | Recruiting | NCT04846920 || A Multicenter, Open-label, Randomized, Phase 1/2 Study of Belzutifan in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma | Phase 1 | Recruiting | NCT05468697 || The BELIEVE-VHL Trial: A Real-world Longitudinal Study on Belzutifan's Effectiveness, Pharmacogenetics, and Pharmacoeconomics in Von Hippel-Lindau (VHL) Syndrome Using the HIF2α Inhibitor Belzutifan | Unknown | Recruiting | NCT07167329 || A Phase 2, Randomized, Active-controlled, Open-label, Multicenter Study of Belzutifan Plus Fulvestrant in Participants With Estrogen Receptor Positive, HER2 Negative Unresectable Locally Advanced or Metastic Breast Cancer After Progression on Previous Endocrine Therapy (LITESPARK-029) | Phase 2 | Recruiting | NCT06428396 || Non-interventional Post-authorization Study of Belzutifan in Adult Patients With Von Hippel-Lindau Disease-associated Renal Cell Carcinoma, Pancreatic Neuroendocrine Tumor and/or Central Nervous System Hemangioblastoma (MK-6482-026) | Unknown | Withdrawn | NCT06554730 || A Phase II Trial of Belzutifan in Patients With Recurrent or Persistent Clear Cell Carcinoma of the Ovary | Unknown | Recruiting | NCT06677190 || An Open-Label, Phase 1 Study to Characterize the Effects of Belzutifan on the Pharmacokinetics of a MATE1/2K Substrate, Metformin, in Healthy Adult Participants | Phase 1 | Recruiting | NCT07121959 || A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC- 7366 in Combination With Belzutifan (WELIREG™) in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma | Phase 1 | Recruiting | NCT06234605 || A Phase 1b Study to Assess the Effects of Belzutifan on 89Zr-DFO-girentuximab Uptake as a Surrogate to Determine CAIX Tumor Expression in Patients With Clear Cell Renal Cell Carcinoma | Phase 1 | Recruiting | NCT07179770 || An Evolutionary Double Bind Phase II Neoadjuvant Study of Abiraterone Acetate, Leuprolide Acetate, and Belzutifan in Men With Regional Prostate Cancer Eligible for Prostatectomy | Unknown | Withdrawn | NCT05574712"
Bristol Myers Squibb,Nivolumab,OPDUALAG,Y,2024-03-01,Prescription Drug,PD-1 | PD-1,Monoclonal Antibody,years and older with unresectable or metastatic melanoma | years and older with unresectable or metastatic melanoma | adult patients with metastatic NSCLC who have disease | adult patients with advanced renal cell carcinoma | adult patients with advanced | adult patients with classical Hodgkin lymphoma | adult patients with recurrent or metastatic squamous cell carcinoma | with disease | adult patients with recurrent or metastatic squamous cell carcinoma | adult patients with locally advanced or metastatic urothelial carcinoma | adult patients with locally advanced or metastatic | patients with metastatic colorectal cancer | patients with metastatic colorectal cancer | patients with metastatic colorectal cancer | adult patients with unresectable or metastatic hepatocellular carcinoma | recurrent or metastatic esophageal squamous cell carcinoma | adult patients with unresectable advanced or metastatic | recurrent or metastatic | adult patients with advanced or metastatic gastric cancer | gastroesophageal junction cancer | and esophageal adenocarcinoma whose tumor | or Stage IV melanoma | adult patients with urothelial carcinoma | stage small cell lung cancer | stage small cell lung cancer | Resectable Non-Small Cell | mutations or anaplastic lymphoma | adult patients with metastatic NSCLC whose tumor | with no EGFR or ALK genomic tumor | adult patients with intermediate or poor risk advanced | adult patients with unresectable or metastatic urothelial carcinoma | completely resected esophageal or gastroesophageal junction cancer | completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease | adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma | per the AJCC Cancer | label trial in patients with previously untreated metastatic | multicenter trial in patients with metastatic | patients with locally advanced or metastatic urothelial carcinoma | eligible patients with unresectable or metastatic | esophageal or gastroesophageal junction cancer who had residual pathologic disease | label trial in patients with previously untreated unresectable advanced | adult patients with unresectable or metastatic melanoma | line treatment of adult patients with metastatic NSCLC whose tumor | line treatment of adult patients with metastatic non-small cell | the treatment of adult patients with metastatic NSCLC who have disease | line treatment of adult patients with intermediate or poor risk advanced | line treatment of adult patients with advanced renal cell carcinoma | the treatment of adult patients with advanced renal cell carcinoma | the treatment of adult patients with advanced endometrial carcinoma | the treatment of adult patients with classical Hodgkin lymphoma | the treatment of adult patients with recurrent or metastatic squamous cell carcinoma | the treatment of adult patients with recurrent or metastatic squamous cell carcinoma | the adjuvant treatment of adult patients with urothelial carcinoma | line treatment of adult patients with unresectable or metastatic urothelial carcinoma | line treatment of adult patients with unresectable or metastatic urothelial carcinoma | the treatment of adult patients with locally advanced or metastatic urothelial carcinoma | the treatment of adult patients with locally advanced or metastatic | line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma | line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma | the treatment of adult patients with unresectable or metastatic hepatocellular carcinoma | the adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer | line treatment of adult patients with unresectable advanced or metastatic | the treatment of adult patients with unresectable advanced | the treatment of adult patients with advanced or metastatic gastric cancer | the treatment of adult patients with advanced or metastatic gastric cancer | the treatment of adult patients with advanced or metastatic gastric cancer | for the treatment of adult patients with metastatic NSCLC who have disease | for the treatment of adult patients with advanced renal cell carcinoma | for the treatment of adult patients with advanced endometrial carcinoma | for the treatment of adult patients with classical Hodgkin lymphoma | for the treatment of adult patients with recurrent or metastatic squamous cell carcinoma | for the treatment of adult patients with recurrent or metastatic squamous cell carcinoma | for the adjuvant treatment of adult patients with urothelial carcinoma | for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma | for the treatment of adult patients with locally advanced or metastatic | for the treatment of adult patients with unresectable or metastatic hepatocellular carcinoma | for the adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer | for the treatment of adult patients with unresectable advanced | for the treatment of adult patients with advanced or metastatic gastric cancer | for the treatment of adult patients with advanced or metastatic gastric cancer | for the treatment of adult patients with advanced or metastatic gastric cancer | adult patients with metastatic non-small cell | adult patients with hepatocellular carcinoma | adult patients with hepatocellular carcinoma | metastatic renal cell carcinoma | positive unresectable or metastatic melanoma | or dMMR metastatic | patients with recurrent or metastatic cutaneous squamous cell carcinoma | Locally Advanced Unresectable or Metastatic Esophageal Cancer | upper respiratory tract infection | and urinary tract infection | or IV melanoma | adult patients with locally advanced or metastatic urothelial cancer | esophageal cancer and gastric cancer | esophageal cancer and gastric cancer | adult patients with intermediate or poor risk advanced renal cell carcinoma | plantar erythrodysesthesia syndrome | and upper respiratory tract infection | line treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma | the treatment of adult patients with unresectable or metastatic melanoma | the treatment of adult patients with metastatic non-small cell | the treatment of adult patients with hepatocellular carcinoma | the treatment of adult patients with hepatocellular carcinoma | for the treatment of adult patients with unresectable or metastatic melanoma | for the treatment of adult patients with metastatic non-small cell | for the treatment of adult patients with hepatocellular carcinoma | for the treatment of adult patients with hepatocellular carcinoma | years of age or older with unresectable or metastatic melanoma | years of age or older with unresectable or metastatic melanoma,"A Randomized Phase II, Double-Blind, Multicenter Study Evaluating the Efficacy and Safety of Autogene Cevumeran Plus Nivolumab Versus Nivolumab as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Urothelial Carcinoma | Unknown | Recruiting | NCT06534983 || A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression | Phase 1 | Recruiting | NCT05111626 || A Phase 1-2 Study of ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma | Phase 1 | Recruiting | NCT03897543 || Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer (Amended Protocol of: Nivolumab, Ipilimumab and COX2-inhibition in Early Stage Colon Cancer: an Unbiased Approach for Signals of Sensitivity: The NICHE TRIAL) | Unknown | Recruiting | NCT03026140 || Safety and Efficacy Evaluation of Low-dose Nivolumab in Combination With AVD as Frontline Therapy for Classic Hodgkin's Lymphoma | Unknown | Recruiting | NCT05772624 || Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab, Bendamustine, Gemcitabine, Vinorelbine (Nivo-BeGEV) in Patients With Relapsed/Refractory Hodgkin Lymphoma | Unknown | Unknown | NCT05660993 || A Phase II Trial of Ipilimumab With and Without Nivolumab in Patients With Relapsed/Refractory Classic Hodgkin Lymphoma | Unknown | Recruiting | NCT04938232 || A Multicenter, Phase II, Open Label, Randomized Trial Evaluating the Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED) | Unknown | Recruiting | NCT04884282 || An Observational Study in Patients Receiving Adjuvant Nivolumab Therapy for Resected Melanoma | Unknown | Recruiting | NCT03771859 || Phase II, Multi-Center Trial of Nivolumab and Brentuximab Vedotin in Patients With Untreated Hodgkin Lymphoma Over the Age of 60 Years or Unable to Receive Standard Adriamycin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) Chemotherapy | Unknown | Recruiting | NCT02758717 || Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor: A Single-Arm, Phase 2 Trial | Phase 2 | Recruiting | NCT04831320 || Nivolumab After Cyclophosphamide and Doxorubicin(CA) Induction Therapy in Previously Treated Advanced Non-squamous Cell Non-small Cell Lung Cancer With PD-L1<10% | Unknown | Unknown | NCT03808480 || A Pilot Study Evaluating a Ketogenic Diet Concomitant to Nivolumab and Ipilimumab in Patients With Metastatic Renal Cell Carcinoma | Unknown | Terminated | NCT05119010 || A Prospective Phase I and II Trial of Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy | Unknown | Terminated | NCT03655444 || A Phase 2 Study of Nivolumab Plus Ipilimumab in Previously Treated Classical Kaposi Sarcoma (CKS) | Phase 2 | Active | NCT03219671 || An Open-Label, Single Arm Phase II Study of Nivolumab in Combination With Ipilimumab in Subjects With Advanced Neuroendocrine Tumors | Unknown | Terminated | NCT03420521 || Phase I/Ib Trial Evaluating the Safety and Efficacy of BET Inhibitor, ZEN003694 With PD-1 Inhibitor, Nivolumab With or Without CTLA-4 Inhibitor, Ipilimumab in Solid Tumors | Unknown | Recruiting | NCT04840589 || A Randomized, Phase III Study of Fotemustine Versus the Combination of Fotemustine and Ipilimumab or the Combination of Ipilimumab and Nivolumab in Patients With Metastatic Melanoma With Brain Metastasis | Unknown | Unknown | NCT02460068 || Phase I Study With Expansion Cohort of Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma | Unknown | Recruiting | NCT06968988"
Bristol Myers Squibb,IPILIMUMAB,YERVOY,Y,2025-05-28,Monoclonal Antibody,CTLA-4,Monoclonal Antibody,positive unresectable or metastatic melanoma | adult patients with unresectable or metastatic hepatocellular carcinoma | patients with metastatic colorectal cancer | years and older with unresectable or metastatic melanoma | adult patients with unresectable or metastatic hepatocellular carcinoma | HCC or melanoma | adult patients with cutaneous melanoma | adult patients with cutaneous melanoma | adult patients with intermediate or poor risk advanced renal cell carcinoma | adult patients with intermediate or poor risk advanced | stage small cell lung cancer | with no EGFR or ALK genomic tumor | stage small cell lung cancer | adult patients with metastatic non-small cell | adult patients with metastatic NSCLC who have disease | small cell lung cancer with no EGFR or ALK genomic tumor | adult patients with metastatic or recurrent non-small cell | adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma | as first line treatment in combination with nivolumab whose tumor | adult patients with unresectable advanced or metastatic | Melanoma YERVOY is indicated for the adjuvant treatment of adult patients with cutaneous melanoma | Melanoma YERVOY is indicated for the adjuvant treatment of adult patients with cutaneous melanoma | adult patients with metastatic NSCLC whose tumor | label trial in patients with previously untreated metastatic | label trial in patients with previously untreated unresectable advanced | recurrent or metastatic | the treatment of unresectable or metastatic melanoma | the treatment of unresectable or metastatic melanoma | line treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma | line treatment of adult patients with intermediate or poor risk advanced | line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma | line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma | line treatment of adult patients with unresectable or metastatic urothelial carcinoma | the treatment of adult patients with unresectable or metastatic hepatocellular carcinoma | line treatment of adult patients with metastatic non-small cell | line treatment of adult patients with metastatic non-small cell | line treatment of adult patients with unresectable advanced or metastatic | use in combination with nivolumab for patients with advanced | for the treatment of unresectable or metastatic melanoma | for the treatment of unresectable or metastatic melanoma | for the treatment of adult patients with unresectable or metastatic hepatocellular carcinoma | for use in combination with nivolumab for patients with advanced,"A Phase 1/2a Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab Administered in Combination With Ipilimumab or Ipilimumab Alone in Participants With Unresectable or Metastatic Melanoma Who Have Progressed on Anti-PD-1 Therapy | Phase 1 | Terminated | NCT03978611 || Uptake and Biodistribution of 89Zirconium-labeled Ipilimumab in Ipilimumab Treated Patients With Metastatic Melanoma | Unknown | Unknown | NCT03313323 || A Randomized Phase II Study of Fixed Dose Ipilimumab (MDX-010) 10 mg/kg Given Alone or in Combination With Two gp100 Peptides Emulsified With Montanide ISA-51 VG for Previously Treated HLA-A * 0201 Positive Subjects With Stage IV Melanoma | Unknown | Active | NCT00357461 || Phase I-II Pilot Study to Evaluate the Immune-mediated Effects of an Autologous Tumor-derived Heat Shock Protein-peptide Complex 96 (HSPPC-96) Combined With Ipilimumab in Patients With Therapeutically Unresectable Stage III or Stage IV Malignant Melanoma | Unknown | Withdrawn | NCT02452281 || A Phase 2 Study of Fianlimab, Cemiplimab, and Ipilimumab in Anti-PD-1 Refractory Melanoma | Phase 2 | Recruiting | NCT06594991"
"EMD Serono, Inc.",AVELUMAB,BAVENCIO,Y,2025-06-13,Monoclonal Antibody,PD-L1,Monoclonal Antibody,years and older with metastatic Merkel cell carcinoma | years and older with metastatic Merkel cell carcinoma | patients with locally advanced or metastatic urothelial carcinoma | adult patients with metastatic NSCLC who have disease | containing chemotherapy Have disease | adult patients with locally advanced or metastatic | adult patients with advanced renal cell carcinoma | adult patients with advanced | the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma | the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma | the treatment of patients with locally advanced or metastatic urothelial carcinoma | the treatment of patients with locally advanced or metastatic urothelial carcinoma | line treatment of patients with advanced renal cell carcinoma | line treatment of patients with advanced renal cell carcinoma | for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma | for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma | for the treatment of patients with locally advanced or metastatic urothelial carcinoma | for the treatment of patients with locally advanced or metastatic urothelial carcinoma,"Pilot Study to Investigate the Safety and Efficacy of Avelumab Monotherapy in Patients With Advanced or Metastatic Adenocarcinoma of the Small Intestine | Unknown | Terminated | NCT03000179 || A Single Arm, Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Avelumab in Combination With the ATR Inhibitor Tuvusertib in Participants With Advanced Urothelial Carcinoma That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder) | Phase 2 | Withdrawn | NCT06424717 || A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors | Unknown | Terminated | NCT03861403 || Phase II Study of Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma (Tide-A Study) | Unknown | Unknown | NCT04698213 || Randomized Phase II Trial of Pre-Operative Gemcitabine, Nab-Paclitaxel, and Hydroxychloroquine With or Without Avelumab (PGHA vs. PGH) | Unknown | Active | NCT03344172 || A Phase I Study of Avelumab, Palbociclib, and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | Unknown | Recruiting | NCT03498378 || A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study | Unknown | Recruiting | NCT04215146 || An Open-label, Phase I/II Multicenter Clinical Trial of VXM01 in Combination With Avelumab in Patients With Progressive Glioblastoma Following Standard Treatment, With or Without Second Surgery | Unknown | Unknown | NCT03750071 || Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC and a Moderate to High Risk | Unknown | Unknown | NCT03341845 || A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial of Adjuvant Avelumab (Anti-PDL-1 Antibody) in Merkel Cell Carcinoma Patients With Lymph Node Metastases | Unknown | Recruiting | NCT03271372 || A Phase II Study of Avelumab in Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma | Unknown | Unknown | NCT03439501 || A Phase II Trial to Evaluate Combination Therapy With Pemetrexed and Avelumab in Previously Treated Patients With MTAP-Deficient Advanced Urothelial Cancer | Unknown | Recruiting | NCT03744793 || A Phase 1b/2, Open-Label Study Evaluating the Safety and Efficacy of KRT-232 in Patients With p53 Wild-Type (p53WT) Merkel Cell Carcinoma (MCC) Who Have Failed Anti-PD-1 or Anti-PD-L1 Immunotherapy, or in Combination With Avelumab in MCC Patients Who Are Anti-PD-1 or Anti-PD-L1 Treatment Naïve | Phase 1 | Unknown | NCT03787602 || Multi-center Phase II Open-label Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma | Unknown | Terminated | NCT05249569"
"Regeneron Pharmaceuticals, Inc.",CEMIPLIMAB,LIBTAYO,Y,2024-06-05,Monoclonal Antibody,PD-1 | PD-L1 | EGFR | ALK | ROS1 | MET | RET | ERK | ATM | ATR | MYC | PROGRAMMED DEATH,Monoclonal Antibody,patients with metastatic cutaneous squamous cell carcinoma | patients with metastatic cutaneous squamous cell carcinoma | or locally advanced | patients with locally advanced or metastatic basal cell carcinoma | adult patients with locally advanced or metastatic | stage small cell lung cancer | stage small cell lung cancer | as adjuvant therapy after tumor resection in adult patients with non-small cell | adult patients with NSCLC whose tumor | the treatment of patients with metastatic cutaneous squamous cell carcinoma | the treatment of patients with metastatic cutaneous squamous cell carcinoma | the treatment of patients with locally advanced or metastatic basal cell carcinoma | the treatment of patients with locally advanced or metastatic urothelial carcinoma | line treatment of adult patients with non-small cell | line treatment of adult patients with NSCLC whose tumor | for the treatment of patients with metastatic cutaneous squamous cell carcinoma | for the treatment of patients with metastatic cutaneous squamous cell carcinoma | for the treatment of patients with locally advanced or metastatic basal cell carcinoma | for the treatment of patients with locally advanced or metastatic urothelial carcinoma,"A Phase 2 Study of Neoadjuvant Cemiplimab for Stage II to IV (M0) Cutaneous Squamous Cell Carcinoma (CSCC) | Phase 2 | Unknown | NCT04154943 || A Phase 1/2 Study of REGN4018 (Ubamatamab), a MUC16×CD3 Bispecific Antibody, Administered Alone or in Combination With Cemiplimab in Patients With Recurrent Ovarian Cancer or Other Recurrent MUC16+ Cancers | Phase 1 | Recruiting | NCT03564340 || A Phase 2 Peri-Operative Study of Treatment With Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Patients With Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC) | Phase 2 | Withdrawn | NCT06384820 || Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors | Unknown | Recruiting | NCT06651593 || A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination With Cemiplimab in Patients With Advanced Solid Tumors | Phase 1 | Recruiting | NCT04626635 || Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Patients With Select Solid Tumors | Phase 2 | Recruiting | NCT04291105 || A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma | Unknown | Recruiting | NCT03969004 || A Phase 2 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma | Phase 2 | Recruiting | NCT06190951 || A Single-arm, Open-label, Phase II Trial of Cemiplimab Plus Gemcitabine as Second-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma Harboring SWItch/Sucrose Non-Fermentable (SWI/SNF) Alterations. | Unknown | Recruiting | NCT06790602 || A Phase II Study of Cabozantinib in Combination With Cemiplimab (Cabo-Cemiplimab) Versus Cabozantinib Alone in Adolescents and Adults With Advanced Adrenocortical Cancer | Unknown | Recruiting | NCT06900595 || A Phase 1b/2a Dose-escalation and Safety/Efficacy Evaluation Study of Pexa-Vec (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) in Combination With Cemiplimab (REGN2810; Anti-PD-1) in Patients With Metastatic or Unresectable Renal Cell Carcinoma (RCC) | Phase 1 | Recruiting | NCT03294083 || Cemiplimab/PEG-Interferon-α Combination for Advanced Cutaneous Squamous Cell Carcinoma (aCSCC) | Unknown | Withdrawn | NCT05729139 || A Phase 1 Study to Assess Safety and Tolerability of Odronextamab (REGN1979) an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, and Cemiplimab (REGN2810), an Anti-Programmed Death-1 Monoclonal Antibody in Patients With B-Cell Malignancies (CLIO-1) | Phase 1 | Recruiting | NCT02651662 || Phase 1/2 Study of REGN4336 (a PSMAxCD3 Bispecific Antibody) Administered Alone or in Combination With Cemiplimab or REGN5678 (a PSMAxCD28 Bispecific Antibody) in Patients With Metastatic Castration-Resistant Prostate Cancer | Phase 1 | Recruiting | NCT05125016 || A Phase II Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma | Unknown | Recruiting | NCT06528769"
"Fresenius Kabi USA, LLC",DOXORUBICIN HYDROCHLORIDE,Doxorubicin,Y,2024-10-14,Prescription Drug,ALK | MET | RET | ATM | ATR | MYC | CAN | DGK,,patients with ovarian cancer | patients with ovarian cancer whose disease | the treatment of patients with ovarian cancer | the treatment of patients with ovarian cancer whose disease | for the treatment of patients with ovarian cancer | for the treatment of patients with ovarian cancer whose disease | cell precursor acute lymphoblastic leukemia | acute myeloblastic leukemia | adult patients with relapsed or refractory classical Hodgkin lymphoma | locally advanced or metastatic breast cancer | metastatic soft tissue sarcoma | metastatic bone sarcoma | metastatic ovarian carcinoma | metastatic transitional cell bladder carcinoma | metastatic thyroid carcinoma | metastatic gastric carcinoma | metastatic bronchogenic carcinoma | overexpressing metastatic gastric | women with axillary lymph node involvement following resection of primary breast cancer | women with axillary lymph node involvement following resection of primary breast cancer | women with breast cancer | women with breast cancer | axillary lymph node positive breast cancer | axillary lymph node positive breast cancer | axillary lymph node positive breast cancer | axillary lymph node positive breast cancer | axillary lymph node positive breast cancer | axillary lymph node positive breast cancer | positive early breast cancer | positive early breast cancer,"Caelyx(R) in Breast Cancer in the Elderly. Pegylated Liposomal Doxorubicin (Caelyx(R)) as Monotherapy in Elderly Patients With Locally Advanced and/or Metastatic Breast Cancer. | Unknown | Terminated | NCT00604968 || A Phase Ib Dose Escalation Study of MK-4827 in Combination With Carboplatin, Carboplatin/Paclitaxel and Carboplatin/Liposomal Doxorubicin in Patients With Advanced Solid Tumors | Unknown | Terminated | NCT01110603 || Phase II Trial of Neoadjuvant Dose-Dense Doxorubicin, Ifosfamide, and Irinotecan (CPT-11) for Advanced Soft Tissue and Recurrent Bone Sarcomas | Unknown | Terminated | NCT00544778 || The Efficacy and Safety of Chidamide Combined With VDDT Regimen（Vinorelbine，Liposomal Doxorubicin，Dexamethasone and Thalidomide） in Relapse and Refractory Patients With Diffuse Large B Cell Lymphoma | Unknown | Unknown | NCT02733380 || Liposomal Doxorubicin and Estramustine Phosphate: A Phase II Study in Taxane Resistant, Hormone Refractory Advanced Prostate Cancer | Unknown | Terminated | NCT00132756 || International Open-label Phase I Dose Escalation Study of Dinutuximab Beta in Combination With Vincristine/Doxorubicin/Cyclophosphamide and Ifosfamide/Etoposide in Pediatric, Adolescent, and Adult Patients With GD2-positive Ewing Sarcoma | Unknown | Recruiting | NCT06839703"
Gland Pharma Limited,CISPLATIN,CISPLATIN,Y,2023-09-26,Chemotherapy,MET | RET | ATM | ATR | MYC,,advanced testicular cancer | mutated Advanced Ovarian Cancer | advanced bladder cancer | the treatment of advanced testicular cancer | the treatment of advanced testicular cancer | the treatment of advanced ovarian cancer | the treatment of advanced bladder cancer | for the treatment of advanced testicular cancer | for the treatment of advanced testicular cancer | for the treatment of advanced ovarian cancer | for the treatment of advanced bladder cancer | as secondary therapy in patients with metastatic ovarian tumor | as secondary therapy in patients with metastatic ovarian tumors refractory | single agent for patients with transitional cell bladder cancer | single agent for patients with transitional cell bladder cancer,"A Randomized Controlled, Open-label, Multicenter Clinical Trial Evaluating the Efficacy and Safety of Carboplatin/Cisplatin + Etoposide + Bemarituzumab Followed by Bemarituzumab Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Followed by Tislelizumab as First-line Treatment for Extensive-stage Small Cell Lung Cancer | Unknown | Recruiting | NCT06897579 || Effects of Acupoint Electro-stimulation on Preventing Nausea and Vomiting Induced by Cisplatin or Oxaliplatin | Unknown | Withdrawn | NCT00430313 || A Phase I Study of the PI3-Kinase Inhibitor BKM120 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors | Unknown | Withdrawn | NCT01971489 || Phase II Trial of Cisplatin Combined with Oral TS-1 in Patients with Advanced Solid Tumors with Different Degrees of Liver Dysfunction | Unknown | Recruiting | NCT03519074 || Paclitaxel (Albumin-bound) Combined With Radiotherapy Compared With Cisplatin Combined With Radiotherapy for the Treatment of Early Stage Nasopharyngeal Carcinoma: a Prospective, Parallel-controlled, Multicenter Phase III Clinical Study | Unknown | Unknown | NCT04766359 || A Randomized, Double Blind, Placebo-controlled, Multicenter Phase II Study to Evaluate Efficacy and Safety of Roniciclib in Subjects With Extensive-stage Disease Small Cell Lung Cancer (SCLC) Who Are Receiving Cisplatin + Etoposide or Carboplatin + Etoposide as First-line Therapy | Unknown | Terminated | NCT02161419 || A National, Multi Center, Randomized, Open-label, Phase II Trial of Tarceva Versus Combination of Gemcitabine Plus Cisplatin as Neoadjuvant Treatment in Stage IIIA-N1,N2 NSCLC With Activating EGFR Mutation in Exon 19 or 21 | Unknown | Unknown | NCT01297101 || A Phase I Study of TS-1, Cisplatin & RAD001 (Everolimus) | Unknown | Terminated | NCT01096199"
Gland Pharma Limited,CARBOPLATIN,CARBOPLATIN,Y,2023-11-09,Chemotherapy,ALK | MET | RET | ATM | ATR,,metastatic ovarian carcinoma | advanced ovarian carcinoma | is indicated for the initial treatment of adults with advanced ovarian carcinoma | is indicated for the initial treatment of adults with advanced ovarian carcinoma | adults with ovarian carcinoma | mutated Advanced Ovarian Cancer | month of age with solid tumor | Gastrointestinal Disorder | Ocular Disorder | treatment of adults with ovarian carcinoma | for treatment of adults with ovarian carcinoma | Advanced Ovarian Carcinoma Carboplatin injection is indicated for the initial treatment of advanced | patients with ovarian cancer | patients with previously treated ovarian carcinoma | the initial treatment of advanced ovarian carcinoma | the palliative treatment of patients with ovarian carcinoma | for the initial treatment of advanced ovarian carcinoma | for the palliative treatment of patients with ovarian carcinoma | it is recommended that breast,"A Randomized Phase III Trial of Carboplatin, Paclitaxel and Thoracic Radiotherapy, With or Without Thalidomide, in Patients With Stage III Non-Small Cell Lung Cancer (NSCLC) | Unknown | Terminated | NCT00004859 || Addition of Decitabine to Carboplatin-Paclitaxel in First-Line Treatment of Advanced Ovarian Cancer: A Phase 2-3, Open-label, Randomised Controlled Trial | Phase 2 | Unknown | NCT02159820 || A Phase I Dose Escalation Study of Capecitabine, Carboplatin and Weekly Paclitaxel and a Phase II Trial of the Same Combination in Patients With Adenocarcinoma of Unknown Primary | Unknown | Terminated | NCT00201734 || Phase II Trial of Temozolomide, Carboplatin and Neupogen in High-Grade Gliomas, Both Newly-Diagnosed and Recurrent | Unknown | Withdrawn | NCT00006263"
"Teva Pharmaceuticals, Inc.",PACLITAXEL,Paclitaxel,Y,2023-11-02,Chemotherapy,ALK | MET | RET | ATM | ATR | REQUIRING,,locally advanced or metastatic breast cancer | breast cancer after failure of combination chemotherapy for metastatic disease | breast cancer after failure of combination chemotherapy for metastatic disease | stage small cell lung cancer | stage small cell lung cancer | mutated locally advanced or metastatic non-small cell | adult patients with metastatic NSCLC who have disease | breast cancer after failure of combination chemotherapy for metastatic disease | breast cancer after failure of combination chemotherapy for metastatic disease | the treatment of breast cancer | the treatment of breast cancer after failure of combination chemotherapy for metastatic disease | the treatment of breast cancer after failure of combination chemotherapy for metastatic disease | line treatment of locally advanced or metastatic non-small cell | line treatment of locally advanced or metastatic non-small cell | line treatment of patients with metastatic colorectal cancer | for the treatment of breast cancer | for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease | for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease | advanced carcinoma | or lung carcinoma | including opportunistic infection | positive breast cancer | positive breast cancer | line treatment of non-small cell | as subsequent therapy for the treatment of advanced carcinoma | as subsequent therapy for the treatment of advanced carcinoma | nonsmall cell lung cancer | nonsmall cell lung cancer | line treatment of nonsmall cell lung cancer | line treatment of nonsmall cell lung cancer,"FDA Comprehensive Approval: Herceptin Hylecta | Unknown | Withdrawn | NCT00021255 || FDA Comprehensive Approval: Herceptin Hylecta | Unknown | Withdrawn | NCT00045032 || FDA Comprehensive Approval: Herceptin Hylecta | Unknown | Withdrawn | NCT00005970 || FDA Comprehensive Approval: Herceptin Hylecta | Unknown | Withdrawn | NCT00004067 || Prospective Observational Investigation of Serum Interleukin-20 Level and Paclitaxel-Associated Neuropathy in Breast Cancer Patients Receiving Paclitaxel Chemotherapy | Unknown | Unknown | NCT05622617 || A Multicenter, Randomized, Open-lable, Parallel-controlled, Phase II Study to Evaluate the Differences of Safety and Efficacy of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma | Unknown | Unknown | NCT05047991"
Cipla USA Inc.,contracept,Paclitaxel,Y,2025-04-02,Chemotherapy,ALK | MET | RET | ATM | ATR,,locally advanced or metastatic breast cancer | breast cancer after failure of combination chemotherapy for metastatic disease | breast cancer after failure of combination chemotherapy for metastatic disease | locally advanced or metastatic breast cancer | locally advanced or metastatic breast cancer | stage small cell lung cancer | stage small cell lung cancer | mutated locally advanced or metastatic non-small cell | locally advanced or metastatic breast cancer | adult patients with metastatic NSCLC who have disease | breast cancer after failure of combination chemotherapy for metastatic disease | breast cancer after failure of combination chemotherapy for metastatic disease | the treatment of breast cancer | the treatment of breast cancer after failure of combination chemotherapy for metastatic disease | the treatment of breast cancer | the treatment of breast cancer after failure of combination chemotherapy for metastatic disease | line treatment of locally advanced or metastatic non-small cell | line treatment of locally advanced or metastatic non-small cell | line treatment of patients with metastatic colorectal cancer | for the treatment of breast cancer | for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease | for the treatment of breast cancer | for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease,"An Open-Label, Multicenter, Phase Ib Trial Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab as Monotherapy and Cevostamab Plus Pomalidomide and Dexamethasone or Cevostamab Plus Daratumumab and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | Unknown | Recruiting | NCT04910568"
Sanofi-Aventis U.S. LLC,DOCETAXEL,Docetaxel,Y,2024-12-06,Chemotherapy,ALK | MET | RET | DGK | ATM | ATR,,patients with locally advanced or metastatic breast cancer | patients with locally advanced or metastatic breast cancer | adult patients with locally advanced or metastatic | stage small cell lung cancer | stage small cell lung cancer | patients with locally advanced or metastatic non-small cell | small cell lung cancer who have not previously received chemotherapy for this condition | mutated locally advanced or metastatic non-small cell | locally advanced or metastatic breast cancer | resistant prostate cancer | resistant prostate cancer | adult patients with metastatic NSCLC who have disease | who have not received prior chemotherapy for advanced disease | patients with advanced gastric | adult patients with advanced | breast cancer and in patients with other tumor | positive breast cancer | positive breast cancer | patients with locally advanced squamous cell carcinoma | the treatment of patients with locally advanced or metastatic breast cancer | the treatment of patients with locally advanced or metastatic breast cancer | the treatment of patients with locally advanced or metastatic urothelial carcinoma | the treatment of patients with locally advanced or metastatic non-small cell | the treatment of patients with metastatic NSCLC whose tumor | the treatment of patients with advanced gastric | the treatment of patients with advanced gastric | the induction treatment of patients with locally advanced squamous cell carcinoma | the induction treatment of patients with locally advanced squamous cell carcinoma | for the treatment of patients with locally advanced or metastatic breast cancer | for the treatment of patients with locally advanced or metastatic breast cancer | for the treatment of patients with locally advanced or metastatic urothelial carcinoma | for the treatment of patients with locally advanced or metastatic non-small cell | for the treatment of patients with metastatic NSCLC whose tumor | for the treatment of patients with advanced gastric | for the treatment of patients with advanced gastric | for the induction treatment of patients with locally advanced squamous cell carcinoma | for the induction treatment of patients with locally advanced squamous cell carcinoma,"A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer | Unknown | Recruiting | NCT04928846 || A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (IDeate-Prostate01) | Unknown | Recruiting | NCT06925737 || A Phase II Trial of Biomarker-driven Intermittent Docetaxel in Metastatic Castration-resistant Prostate Cancer (mCRPC) | Unknown | Terminated | NCT04918810 || A Randomized Phase 2 Clinical Trial Of Docetaxel With Or Without PF-3512676 As First-Line Treatment Of Patients With Advanced Breast Cancer | Phase 2 | Withdrawn | NCT00471159 || Phase II Study of Neoadjuvant Adebrelimab, Docetaxel, Oxaliplatin, and S-1 in Patients With Resectable Advanced Gastric Cancer | Unknown | Recruiting | NCT06475417 || A Randomized Phase 3 Study of MRTX849 Versus Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation | Unknown | Recruiting | NCT04685135"
"Hospira, Inc.",DOCETAXEL ANHYDROUS,Docetaxel,Y,2025-01-20,Chemotherapy,ALK | MET | RET | DGK | ATM | ATR | ALK | MET | RET | DGK | ATM | ATR | ALK | MET | RET | DGK | ATM | ATR,,patients with locally advanced or metastatic breast cancer | patients with locally advanced or metastatic breast cancer | adult patients with locally advanced or metastatic | stage small cell lung cancer | stage small cell lung cancer | patients with locally advanced or metastatic non-small cell | small cell lung cancer who have not previously received chemotherapy for this condition | mutated locally advanced or metastatic non-small cell | locally advanced or metastatic breast cancer | resistant prostate cancer | resistant prostate cancer | adult patients with metastatic NSCLC who have disease | who have not received prior chemotherapy for advanced disease | patients with advanced gastric | adult patients with advanced | who have not received prior chemotherapy for advanced disease | breast cancer and in patients with other tumor | locally advanced or metastatic breast cancer | positive breast cancer | positive breast cancer | patients with locally advanced squamous cell carcinoma | adult patients with locally advanced or metastatic | locally advanced or metastatic breast cancer | the treatment of patients with locally advanced or metastatic breast cancer | the treatment of patients with locally advanced or metastatic breast cancer | the treatment of patients with locally advanced or metastatic urothelial carcinoma | the treatment of patients with locally advanced or metastatic non-small cell | the treatment of patients with metastatic NSCLC whose tumor | the treatment of patients with advanced gastric | the treatment of patients with advanced gastric | the induction treatment of patients with locally advanced squamous cell carcinoma | the induction treatment of patients with locally advanced squamous cell carcinoma | for the treatment of patients with locally advanced or metastatic breast cancer | for the treatment of patients with locally advanced or metastatic breast cancer | for the treatment of patients with locally advanced or metastatic urothelial carcinoma | for the treatment of patients with locally advanced or metastatic non-small cell | for the treatment of patients with metastatic NSCLC whose tumor | for the treatment of patients with advanced gastric | for the treatment of patients with advanced gastric | for the induction treatment of patients with locally advanced squamous cell carcinoma | for the induction treatment of patients with locally advanced squamous cell carcinoma | patients with locally advanced or metastatic breast cancer | patients with locally advanced or metastatic breast cancer | adult patients with locally advanced or metastatic | stage small cell lung cancer | stage small cell lung cancer | patients with locally advanced or metastatic non-small cell | small cell lung cancer who have not previously received chemotherapy for this condition | mutated locally advanced or metastatic non-small cell | locally advanced or metastatic breast cancer | resistant prostate cancer | resistant prostate cancer | adult patients with metastatic NSCLC who have disease | who have not received prior chemotherapy for advanced disease | patients with advanced gastric | adult patients with advanced | who have not received prior chemotherapy for advanced disease | breast cancer and in patients with other tumor | locally advanced or metastatic breast cancer | positive breast cancer | positive breast cancer | patients with locally advanced squamous cell carcinoma | adult patients with locally advanced or metastatic | locally advanced or metastatic breast cancer | the treatment of patients with locally advanced or metastatic breast cancer | the treatment of patients with locally advanced or metastatic breast cancer | the treatment of patients with locally advanced or metastatic urothelial carcinoma | the treatment of patients with locally advanced or metastatic non-small cell | the treatment of patients with metastatic NSCLC whose tumor | the treatment of patients with advanced gastric | the treatment of patients with advanced gastric | the induction treatment of patients with locally advanced squamous cell carcinoma | the induction treatment of patients with locally advanced squamous cell carcinoma | for the treatment of patients with locally advanced or metastatic breast cancer | for the treatment of patients with locally advanced or metastatic breast cancer | for the treatment of patients with locally advanced or metastatic urothelial carcinoma | for the treatment of patients with locally advanced or metastatic non-small cell | for the treatment of patients with metastatic NSCLC whose tumor | for the treatment of patients with advanced gastric | for the treatment of patients with advanced gastric | for the induction treatment of patients with locally advanced squamous cell carcinoma | for the induction treatment of patients with locally advanced squamous cell carcinoma | patients with locally advanced or metastatic breast cancer | patients with locally advanced or metastatic breast cancer | adult patients with locally advanced or metastatic | stage small cell lung cancer | stage small cell lung cancer | patients with locally advanced or metastatic non-small cell | small cell lung cancer who have not previously received chemotherapy for this condition | mutated locally advanced or metastatic non-small cell | locally advanced or metastatic breast cancer | resistant prostate cancer | resistant prostate cancer | adult patients with metastatic NSCLC who have disease | who have not received prior chemotherapy for advanced disease | patients with advanced gastric | adult patients with advanced | who have not received prior chemotherapy for advanced disease | breast cancer and in patients with other tumor | locally advanced or metastatic breast cancer | positive breast cancer | positive breast cancer | patients with locally advanced squamous cell carcinoma | adult patients with locally advanced or metastatic | locally advanced or metastatic breast cancer | the treatment of patients with locally advanced or metastatic breast cancer | the treatment of patients with locally advanced or metastatic breast cancer | the treatment of patients with locally advanced or metastatic urothelial carcinoma | the treatment of patients with locally advanced or metastatic non-small cell | the treatment of patients with metastatic NSCLC whose tumor | the treatment of patients with advanced gastric | the treatment of patients with advanced gastric | the induction treatment of patients with locally advanced squamous cell carcinoma | the induction treatment of patients with locally advanced squamous cell carcinoma | for the treatment of patients with locally advanced or metastatic breast cancer | for the treatment of patients with locally advanced or metastatic breast cancer | for the treatment of patients with locally advanced or metastatic urothelial carcinoma | for the treatment of patients with locally advanced or metastatic non-small cell | for the treatment of patients with metastatic NSCLC whose tumor | for the treatment of patients with advanced gastric | for the treatment of patients with advanced gastric | for the induction treatment of patients with locally advanced squamous cell carcinoma | for the induction treatment of patients with locally advanced squamous cell carcinoma,
"Fresenius Kabi USA, LLC",GEMCITABINE INTRAVESICAL,GEMCITABINE,Y,2024-10-14,Chemotherapy,MET | RET | ATM | ALK | MET | RET | ATM,,adult patients with muscle invasive bladder cancer | with carcinoma | with or without papillary tumor | patients with advanced ovarian cancer | adult patients with advanced | mutated Advanced Ovarian Cancer | stage small cell lung cancer | stage small cell lung cancer | pancreatic cancer | locally advanced or metastatic breast cancer | locally advanced or metastatic breast cancer | patients with metastatic breast cancer | patients with metastatic breast cancer | adult patients with metastatic NSCLC who have disease | adult patients with unresectable or metastatic hepatocellular carcinoma | ovarian cancer in women with disease | the treatment of patients with advanced ovarian cancer | the treatment of patients with advanced gastric | line treatment of patients with metastatic breast cancer | line treatment of patients with metastatic breast cancer | line treatment of patients with metastatic colorectal cancer | for the treatment of patients with advanced ovarian cancer | for the treatment of patients with advanced gastric | line treatment for patients with locally advanced,"A Phase II Study of the Association of Glivec® (Imatinib Mesylate, Formerly Known as STI 571) Plus Gemzar® (Gemcitabine) in Patients With Unresectable, Refractory, Malignant Mesothelioma Expressing Either PDGFR-Beta or C-Kit | Unknown | Unknown | NCT00551252 || A Phase II Trial of Gemcitabine and Erlotinib (GE) Plus Proton-chemotherapy (PCT) and Capox for Locally Advanced Pancreatic Cancer (LAPC) | Unknown | Terminated | NCT01683422"
Mylan Institutional LLC,GEMCITABINE HYDROCHLORIDE,Gemcitabine,Y,2024-11-11,Chemotherapy,ALK | MET | RET | ATM,,patients with advanced ovarian cancer | adult patients with advanced | mutated Advanced Ovarian Cancer | stage small cell lung cancer | stage small cell lung cancer | pancreatic cancer | locally advanced or metastatic breast cancer | locally advanced or metastatic breast cancer | patients with metastatic breast cancer | patients with metastatic breast cancer | adult patients with metastatic NSCLC who have disease | locally advanced or metastatic breast cancer | adult patients with unresectable or metastatic hepatocellular carcinoma | mutated Advanced Ovarian Cancer | ovarian cancer in women with disease | the treatment of patients with advanced ovarian cancer | the treatment of patients with advanced gastric | line treatment of patients with metastatic breast cancer | line treatment of patients with metastatic breast cancer | line treatment of patients with metastatic colorectal cancer | for the treatment of patients with advanced ovarian cancer | for the treatment of patients with advanced gastric | line treatment for patients with locally advanced,
BluePoint Laboratories,FLUOROURACIL,Fluorouracil,Y,2025-01-13,Chemotherapy,MET | ATM | ATR | ATR,,multiple actinic or solar keratoses | superficial basal cell carcinoma | Adenocarcinoma of the Breast | Adenocarcinoma of the Breast | patients with • Adenocarcinoma of the Colon,"A Randomised, Non-Comparative, Multicentre, Phase II, Parallel-Group Trial Of ZD1839 (Iressa™) In Combination With 5 Fluorouracil, Leucovorin And Cpt-11 (Irinotecan) In Patients With Metastatic Colorectal Cancer | Unknown | Withdrawn | NCT00233623 || Maintenance Treatment With Capecitabine Plus Cetuximab After First-line 5-Fluorouracil-based Chemotherapy Plus Cetuximab for Patients With RAS Wild-type Metastatic Colorectal Cancer: a Single Arm, Open-label, Multi-center Clinical Trial | Unknown | Unknown | NCT02717923 || The Efficacy and Safety of Using Intralesional 5-fluorouracil for Basal Cell Carcinoma: Clinical Trail | Unknown | Recruiting | NCT06150144 || A Randomized Controlled, Open-label, Multicenter Phase III Clinical Trial to Evaluate the Effectiveness and Safety of Hepatic Arterial Infusion Chemotherapy (HAIC) of Oxaliplatin, 5-fluorouracil and Leucovorin (mFOLFOX7) Combined With Apatinib and Camrelizumab Versus Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification. | Unknown | Unknown | NCT05313282"
Dr. Reddy's Laboratories Inc.,Except,FLUOROURACIL,Y,2025-07-11,Prescription Drug,ATM,,multiple actinic or solar keratoses of the face | anterior scalp,"An Open-Label, Multicenter, Phase I Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of Cevostamab (BFCR4350A) in Patients With Relapsed or Refractory Multiple Myeloma | Unknown | Recruiting | NCT03275103"
"Golden State Medical Supply, Inc.",METHOTREXATE,Methotrexate,Y,2025-02-10,Vaccine,MET | RET | DGK | ATM | ATR | MYC,,adult and pediatric patients with acute lymphoblastic leukemia | adult patients with relapsed or refractory classical Hodgkin lymphoma | adults with breast cancer | adults with breast cancer | adults with squamous cell carcinoma | adults with rheumatoid arthritis | pediatric patients with polyarticular Juvenile Idiopathic Arthritis | adult and pediatric patients with meningeal leukemia | adult and pediatric patients with meningeal leukemia | the treatment of adult and pediatric patients with acute lymphoblastic leukemia | the prophylaxis and treatment of meningeal leukemia | the treatment of adults with breast cancer | the treatment of adults with breast cancer | the treatment of adults with squamous cell carcinoma | the treatment of adults with rheumatoid arthritis | the treatment of pediatric patients with polyarticular Juvenile Idiopathic Arthritis | neoplastic disease | for the treatment of adult and pediatric patients with acute lymphoblastic leukemia | for the prophylaxis and treatment of meningeal leukemia | for the treatment of adults with breast cancer | for the treatment of adults with breast cancer | for the treatment of adults with squamous cell carcinoma | for the treatment of adults with rheumatoid arthritis | for the treatment of pediatric patients with polyarticular Juvenile Idiopathic Arthritis | malignant disease | adults and pediatric patients with acute lymphoblastic leukemia | adults with relapsed or refractory | cell lymphoma | cutaneous T-cell | Treatment of adults and pediatric patients with acute lymphoblastic leukemia | combination chemotherapy regimen treatment of adults with relapsed or refractory,"Different Dose of Methotrexate for the Treatment of Meningeal Carcinomatosis | Unknown | Unknown | NCT02590510 || Observational Study of Hair Fall in Rheumatoid Arthritis Patients Treated With Low Dose Methotrexate | Unknown | Unknown | NCT02591823 || An Open Label Pilot Study of Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event: Comparison With CHAMPS Results. | Unknown | Withdrawn | NCT00037115 || Methotrexate Combined With Tofacitinib in the Treatment of Active Rheumatoid Arthritis With a Myeloid-stromal Pathotype: a Randomized, Controlled, Open Label, Multicenter Clinical Study | Unknown | Recruiting | NCT06301373 || A Multicenter, Single-arm, Open II Phase Clinical Trial Evaluating the Efficacy of Chidamide Combined With Prednisone, Cyclophosphamide, Etoposide, and Methotrexate (PECM) in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | Unknown | Unknown | NCT03321890"
"Fresenius Kabi USA, LLC",METHOTREXATE SODIUM,Methotrexate,Y,2025-08-19,Vaccine,MET | RET | DGK | ATM | ATR,,adult and pediatric patients with acute lymphoblastic leukemia | adult patients with relapsed or refractory classical Hodgkin lymphoma | adults with breast cancer | adults with breast cancer | adults with squamous cell carcinoma | adults with rheumatoid arthritis | pediatric patients with polyarticular Juvenile Idiopathic Arthritis | adult and pediatric patients with meningeal leukemia | adult and pediatric patients with meningeal leukemia | the treatment of adult and pediatric patients with acute lymphoblastic leukemia | the prophylaxis and treatment of meningeal leukemia | the treatment of adults with breast cancer | the treatment of adults with breast cancer | the treatment of adults with squamous cell carcinoma | the treatment of adults with rheumatoid arthritis | the treatment of pediatric patients with polyarticular Juvenile Idiopathic Arthritis | neoplastic disease | for the treatment of adult and pediatric patients with acute lymphoblastic leukemia | for the prophylaxis and treatment of meningeal leukemia | for the treatment of adults with breast cancer | for the treatment of adults with breast cancer | for the treatment of adults with squamous cell carcinoma | for the treatment of adults with rheumatoid arthritis | for the treatment of pediatric patients with polyarticular Juvenile Idiopathic Arthritis,
Baxter Healthcare Corporation,CYCLOPHOSPHAMIDE,CYCLOPHOSPHAMIDE,Y,2025-01-30,Chemotherapy,ALK | MET | RET | KIT | DGK | ATM | ATR | MYC | RETINOBLASTOMA,,malignant lymphoma | or small lymphocytic lymphoma | cell type lymphoma | histiocytic lymphoma | lymphoma multiple myeloma leukemia | adult patients with chronic lymphocytic leukemia | chronic granulocytic leukemia | acute myelogenous and monocytic leukemia | adenocarcinoma of the ovary retinoblastoma carcinoma | who have not received prior chemotherapy for advanced disease | disseminated disease | adenocarcinoma of the ovary retinoblastoma carcinoma of the breast | breast carcinoma | malignant disease | breast carcinoma | malignant disease | Adenocarcinoma of the Breast | biopsy proven minimal change nephrotic syndrome | nephrotic syndrome in adults or other renal disease | the treatment of biopsy proven minimal change nephrotic syndrome | for the treatment of biopsy proven minimal change nephrotic syndrome | for the treatment of biopsy proven minimal change nephrotic syndrome,"Early Identification and Evaluation of the Cardiotoxicity of Cyclophosphamide in Hematopoietic Stem Cell Transplantation : Based on Spot Tracking Ultrasound | Unknown | Unknown | NCT05150080 || PHASE 1/2 STUDY TO EVALUATE PALBOCICLIB (IBRANCE®) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE OR IN COMBINATION WITH TOPOTECAN AND CYCLOPHOSPHAMIDE IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS | Phase 1 | Recruiting | NCT03709680 || Lead-In and Phase II Study of Clofarabine, Etoposide, Cyclophosphamide [CEC], Liposomal Vincristine (VCR), Dexamethasone and Bortezomib in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL) | Unknown | Recruiting | NCT03136146 || Phase Ib of Cyclophosphamide, Pomalidomide, Dexamethasone and Daratumumab (CPD-DARA) in Patients With Relapsed/Refractory Multiple Myeloma. (The CPD-DARA Study) | Unknown | Recruiting | NCT04667663 || Efficacy and Safety of Allogeneic Hematopoietic Cell Transplantation Using Post-transplantation Cyclophosphamide for Graft-versus-host Disease Prophylaxis in Higher-risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, and Secondary AML Patients | Unknown | Recruiting | NCT06098313 || Randomized Comparison of Cyclophosphamide Versus Fludarabine in Addition to Anti-thymocyte Globulin for the Conditioning Therapy in Allogeneic Hematopoietic Cell Transplantation for Adult Acquired Aplastic Anemia | Unknown | Unknown | NCT01145976 || A Randomised Phase II Trial of Cyclophosphamide and Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma (RRMM) Patients Who Have Relapsed After Treatment With Thalidomide, Lenalidomide and Bortezomib. | Unknown | Unknown | NCT02461888 || A Phase Ib/II Trial of Combined SGN-35 (BrentuximabVedotin) Therapy With Cyclophosphamide, Procarbazine, Prednisone, Etoposide and Mitoxantrone (BrEPEM) for Older Patients With Untreated Hodgkin Lymphoma (HL) | Unknown | Recruiting | NCT03576378"
"Slate Run Pharmaceuticals, LLC",CYCLOPHOSPHAMIDE FOR INJECTION,Cyclophosphamide,Y,2025-04-02,Chemotherapy,ALK | MET | RET | KIT | DGK | ATM | ATR | MYC | RETINOBLASTOMA,,malignant lymphoma | or small lymphocytic lymphoma | cell type lymphoma | histiocytic lymphoma | adult patients with chronic lymphocytic leukemia | chronic granulocytic leukemia | acute myelogenous and monocytic leukemia | who have not received prior chemotherapy for advanced disease | disseminated disease | Adenocarcinoma of the Breast | biopsy proven minimal change nephrotic syndrome | nephrotic syndrome in adults or other renal disease | breast carcinoma | malignant disease | the treatment of biopsy proven minimal change nephrotic syndrome | for the treatment of biopsy proven minimal change nephrotic syndrome,
Mylan Pharmaceuticals Inc.,ETOPOSIDE,Etoposide,Y,2016-04-19,Prescription Drug,MET | ATM,,a wide variety of malignancies | in the management of the following neoplasm | advanced testicular cancer | Refractory testicular tumor | USP in combination therapy with other approved chemotherapeutic agents in patients with refractory,"Cyclosporine Modulation of Drug Resistance in Combination With Pravastatin, Mitoxantrone, and Etoposide for Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML): A Phase 1/2 Study | Phase 1 | Terminated | NCT01342887 || Diffuse Large B Cell And Peripheral T Cell Non-Hodgkin's Lymphomas (NHL) In The Elderly. Influence Of Prolonged Oral Etoposide Added To CHOP Combination Chemotherapy In Patients With Good Physiological Status. An EORTC Randomized Phase II-III Trial Including Geriatric Assessment And Quality Of Life | Unknown | Terminated | NCT00060385 || Targeted Busulfan, Fludarabine, Etoposide Conditioning Regimen for Hematopoietic Stem Cell Transplantation in Childhood and Adolescent Acute Lymphoblastic Leukemia | Unknown | Unknown | NCT02047578 || A Phase I Study of M3814 in Combination With MEC in Patients With Relapsed or Refractory Acute Myeloid Leukemia | Unknown | Suspended | NCT03983824 || A Phase 2 Randomized, Open-label, Multicenter Trial of Apatinib and Etoposide Capsule Versus Apatinib in Patients With Platinum Resistant or Refractory Ovarian Cancer | Phase 2 | Unknown | NCT04383977 || A Phase 1/2 Study of the Bromodomain Inhibitor Molibresib in Combination With Etoposide/Platinum in Patients With NUT Carcinoma | Phase 1 | Withdrawn | NCT04116359"
"H2-Pharma, LLC",ETOPOSIDE PHOSPHATE,ETOPOPHOS,Y,2024-12-31,Prescription Drug,MET | DGK | ATM,,Refractory testicular tumor | patients with refractory testicular tumor | pediatric patients with refractory | patients with small cell lung cancer | patients with small cell lung cancer | patients with small cell lung cancer,
"Upsher-Smith Laboratories, LLC",IMATINIB MESYLATE,imatinib,Y,2024-12-04,Kinase Inhibitor,EGFR | ALK | MET | RET | C-KIT | KIT | ERK | ATM | ATR | IFN | PDGF,Kinase Inhibitor,adult patients following resection of Kit (CD117) positive GIST | adult patients following resection of Kit (CD117) positive GIST,"A Single-center, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Lenvatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Who Have Failed Treatment With Imatinib, Sunitinib, and Regorafenib | Unknown | Recruiting | NCT07096609 || Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia | Unknown | Unknown | NCT02317159 || Imatinib Mesylate (Glivec) as Maintenance Therapy After Cytogenetic Response With Nilotinib (AMN107, Tasigna) First Line in Newly Diagnosed Chronic Myelogenous Leukemia | Unknown | Recruiting | NCT01316250 || Phase 2 Trial of Ponatinib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST) Following Failure or Intolerance of Prior Therapy With Imatinib | Phase 2 | Unknown | NCT03171389 || A Phase III Multi-center, Open-label, Randomized Study of the Efficacy of Nilotinib Versus Imatinib in Adult Patients With Ph+ CML in Early CP Who Have a Suboptimal Molecular Response to Imatinib | Unknown | Unknown | NCT01400074 || A Phase I Study of Imatinib Mesylate and SU011248 for Patients With Gastrointestinal Stromal Tumors | Unknown | Terminated | NCT00573404"
"Shorla Oncology Inc.,",IMATINIB ORAL,IMKELDI,Y,2024-12-05,Kinase Inhibitor,EGFR | ALK | MET | RET | C-KIT | KIT | ERK | ATM | ATR | IFN | PDGF,Kinase Inhibitor,adult patients following resection of Kit (CD117) positive GIST,An Open Label Multicentric Phase 1 Study of Oral PI3K/mTOR Inhibitor P7170 in Patients With Advanced Refractory Solid Tumors. | Phase 1 | Suspended | NCT01762410
"Teva Pharmaceuticals, Inc.",SORAFENIB,Sorafenib,Y,2022-07-01,Kinase Inhibitor,THE | ARE,Kinase Inhibitor,adult patients with unresectable hepatocellular carcinoma | adult patients with unresectable hepatocellular carcinoma | adult patients with unresectable hepatocellular carcinoma | adult patients with unresectable hepatocellular carcinoma | differentiated thyroid carcinoma | patients with locally recurrent or metastatic | that is refractory | the treatment of Unresectable hepatocellular carcinoma | the treatment of Unresectable hepatocellular carcinoma | the treatment of patients with unresectable hepatocellular carcinoma | the treatment of patients with unresectable hepatocellular carcinoma | the treatment of patients with locally recurrent or metastatic | for the treatment of patients with unresectable hepatocellular carcinoma | for the treatment of patients with unresectable hepatocellular carcinoma | for the treatment of patients with locally recurrent or metastatic | adult patients with advanced renal cell carcinoma | adult patients with advanced | the treatment of patients with advanced renal cell carcinoma | the treatment of patients with advanced gastric | for the treatment of patients with advanced renal cell carcinoma | for the treatment of patients with advanced gastric | for the treatment of patients with advanced renal cell carcinoma | for the treatment of patients with advanced gastric | for the treatment of patients with advanced renal cell carcinoma | for the treatment of patients with advanced gastric,"Phase I/II Study of Sorafenib Added to Busulfan and Fludarabine Conditioning Regimen in Patients With Relapsed/Refractory AML Undergoing Stem Cell Transplantation | Unknown | Recruiting | NCT03247088 || Phase II Pilot Trial of ""Chemo-Switch"" Regimen of Biochemotherapy Followed by Daily Low-Dose Temozolomide Plus Sorafenib in Advanced Melanoma | Unknown | Terminated | NCT00673361 || Population Pharmacokinetics and Pharmacodynamics of Sorafenib in HCC Patients With Child-Pugh B Liver Cirrhosis (SORBE-trial) | Unknown | Terminated | NCT04051853 || A Multi-Center, Non-Controlled Clinical Study of Sorafenib Adjuvant Therapy in Locally Advanced Renal-Cell Carcinoma After Radical Nephrectomy | Unknown | Unknown | NCT01041482"
Mylan Pharmaceuticals Inc.,SUNITINIB MALATE,Sunitinib,Y,2023-08-15,Kinase Inhibitor,ALK | MET | RET | ERK | ATM | ATR,Kinase Inhibitor,adult patients with gastrointestinal stromal tumor | after disease | adult patients with advanced renal cell carcinoma | adult patients with advanced | differentiated pancreatic neuroendocrine tumor | in adult patients with unresectable locally advanced or metastatic disease | in adult patients with unresectable locally advanced or metastatic disease | metastatic renal cell carcinoma | Cardiac Hypertension | the treatment of adult patients with gastrointestinal stromal tumor | the treatment of adult patients with advanced renal cell carcinoma | the treatment of adult patients with advanced endometrial carcinoma | for the treatment of adult patients with gastrointestinal stromal tumor | for the treatment of adult patients with advanced renal cell carcinoma | for the treatment of adult patients with advanced endometrial carcinoma | for the treatment of adult patients with gastrointestinal stromal tumor | for the treatment of adult patients with advanced renal cell carcinoma | for the treatment of adult patients with advanced endometrial carcinoma | foot syndrome | well differentiated pancreatic neuroendocrine tumor | Stomatitis Includes mucosal inflammation,
"Sun Pharmaceutical Industries, Inc.",ERLOTINIB,Erlotinib,Y,2019-11-06,Kinase Inhibitor,EGFR | ALK | MET | ATM | MYC,Kinase Inhibitor,NSCLC and pancreatic cancer | stage small cell lung cancer | adult patients with metastatic NSCLC whose tumor | stage small cell lung cancer | adult patients with metastatic non-small cell | adult patients with metastatic NSCLC who have disease | unresectable or metastatic pancreatic cancer | adult patients with locally advanced or metastatic | adult patients with unresectable or metastatic hepatocellular carcinoma | line treatment of patients with locally advanced | The treatment of patients with metastatic non-small cell | the treatment of patients with metastatic NSCLC whose tumor,"A Phase 1b/2 Study of ASP2215 in Combination With Erlotinib in Subjects With EGFR Activating Mutation-Positive (EGFRm+) Advanced NSCLC Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI) | Phase 1 | Terminated | NCT02495233 || Phase I Trial of Cetuximab and Erlotinib (EGFR Inhibitors) and SIR-Spheres (Yttrium Microspheres) in Patients With Advanced Malignancies and Liver Metastases | Phase 1 | Withdrawn | NCT01432119 || A Phase II Open-Label Trial to Evaluate the Efficacy and Toxicity of Tarceva (Erlotinib) in Women With Metastatic, Hormone Receptor Negative and Her2-Negative Breast Cancer | Unknown | Terminated | NCT00597597 || Phase I Study of Erlotinib (Tarceva) in Combination With AT-101 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) | Unknown | Withdrawn | NCT00934076 || The Value of Radiotherapy in the Oligometastatic Non-squamous Non-small Cell Lung Cancer With Clinical Benefits From Erlotinib as Second-line Treatment: a Randomized Controlled Phase II Clinical Trial | Unknown | Unknown | NCT01796288"
MSN LABORATORIES PRIVATE LIMITED,ERLOTINIB HYDROCHLORIDE,Erlotinib,Y,2019-12-03,Kinase Inhibitor,EGFR | ALK | MET | ATM | MYC | EGFR | ALK | MET | ATM | MYC | EGFR | ALK | MET | ATM | MYC,Kinase Inhibitor,NSCLC and pancreatic cancer | stage small cell lung cancer | adult patients with metastatic NSCLC whose tumor | stage small cell lung cancer | adult patients with metastatic non-small cell | adult patients with metastatic NSCLC who have disease | unresectable or metastatic pancreatic cancer | adult patients with locally advanced or metastatic | adult patients with unresectable or metastatic hepatocellular carcinoma | line treatment of patients with locally advanced | The treatment of patients with metastatic non-small cell | the treatment of patients with metastatic NSCLC whose tumor | NSCLC and pancreatic cancer | stage small cell lung cancer | adult patients with metastatic NSCLC whose tumor | stage small cell lung cancer | adult patients with metastatic non-small cell | adult patients with metastatic NSCLC who have disease | unresectable or metastatic pancreatic cancer | adult patients with locally advanced or metastatic | adult patients with unresectable or metastatic hepatocellular carcinoma | line treatment of patients with locally advanced | The treatment of patients with metastatic non-small cell | the treatment of patients with metastatic NSCLC whose tumor | NSCLC and pancreatic cancer | stage small cell lung cancer | adult patients with metastatic NSCLC whose tumor | stage small cell lung cancer | adult patients with metastatic non-small cell | adult patients with metastatic NSCLC who have disease | unresectable or metastatic pancreatic cancer | adult patients with locally advanced or metastatic | adult patients with unresectable or metastatic hepatocellular carcinoma | line treatment of patients with locally advanced | The treatment of patients with metastatic non-small cell | the treatment of patients with metastatic NSCLC whose tumor,
ImClone LLC,CETUXIMAB,ERBITUX,Y,2024-07-25,Therapeutic Protein,EGFR | ALK | MET | RET | BRAF | BRAF V600E | ATM | ATR,Therapeutic Protein,patients with metastatic colorectal cancer | patients with metastatic colorectal cancer | adult patients with metastatic colorectal cancer | adult patients with metastatic colorectal cancer | adult patients with metastatic NSCLC who have disease | patients with recurrent or metastatic HNSCC with disease | mutant colorectal cancer | mutant colorectal cancer | locally or regionally advanced squamous cell carcinoma | locally or regionally advanced squamous cell carcinoma | patients with recurrent locoregional disease | patients with recurrent locoregional disease or metastatic | Head and Neck Cancer Locally or regionally advanced squamous cell carcinoma | Head and Neck Cancer Locally or regionally advanced squamous cell carcinoma,"An Exploratory Clinical Study to Evaluate the Efficacy and Safety of Penpulimab in Combination With Cetuximab as First-line Treatment in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/MSCCHN) | Unknown | Recruiting | NCT05260671 || A Phase I Study of Anti-CD3 x Cetuximab-Armed Activated T Cells, Low Dose IL-2, and GM-CSF for EGFR-Positive, Advanced Solid Tumors | Unknown | Active | NCT01081808 || Biomarker-Panel Enriched Maintenance Treatment With Cetuximab Monotherapy Versus Continuation After Induction Treatment With Chemotherapy + Cetuximab in Metastatic Colorectal Cancer (mCRC) | Unknown | Unknown | NCT02978313 || A Multicenter, Open-label, Parallel-group，Randomised, Phase IIb Trial of Efficacy and Safety of Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI Versus Ametumumab or Cetuximab in Combination With FOLFIRI in Patients With RAS Wild-type Advanced Colorectal Cancer | Unknown | Unknown | NCT05684211 || Open Label Randomized Phase II, Multicentre, Pilot Study to Evaluate Safety and Efficacy of the Combination of Cetuximab and Concomitant-Boost Accelerated Radiotherapy Followed or Not by a Complementary Treatment With Cetuximab in Patients With Locally Advanced Oropharynx Squamous Cell Carcinoma. | Unknown | Unknown | NCT00251381 || A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of CDX-3379 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma | Phase 2 | Terminated | NCT03254927 || Prospective Phase II Study on Skin Toxicity on Low-Dose Doxycycline in Metastatic Colorectal Cancer Patients During Cetuximab and Panitumumab Treatment | Unknown | Unknown | NCT01380262"
Amgen,PANITUMUMAB,Vectibix,Y,2025-06-03,Chemotherapy,EGFR | ALK | MET | RET | ATM | KRAS,,patients with RAS -mutant mCRC unless used in combination with sotorasib in KRAS G12C-mutated mCRC | patients with metastatic colorectal cancer | patients with metastatic colorectal cancer | patients with colorectal cancer | patients with colorectal cancer | the treatment of patients with colorectal cancer | the treatment of patients with colorectal cancer,"FDA Comprehensive Approval: LUMAKRAS | Unknown | Active | NCT04380753 || FDA Comprehensive Approval: LUMAKRAS | Unknown | Active | NCT04303780 || FDA Comprehensive Approval: LUMAKRAS | Unknown | Active | NCT04185883 || FDA Comprehensive Approval: LUMAKRAS | Unknown | Active | NCT03600883 || FDA Comprehensive Approval: LUMAKRAS | Unknown | Active | NCT05198934 || Study Evaluating 89Zr Panitumumab for Assessment of Indeterminate Metastatic Lesions on 18F-FDG-PET/CT in Head and Neck Squamous Cell Carcinoma | Unknown | Recruiting | NCT05747625 || Safety and Efficacy of the Addition of Simvastatin to Panitumumab in K-ras Mutant Advanced or Metastatic Colorectal Cancer Patients. A Single-Arm, Multicenter, Phase II Study Using a Simon Two Stage Design. | Unknown | Unknown | NCT01110785 || Phase II Pilot Study of FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer | Unknown | Unknown | NCT04169347 || First-line FOLFOX-4 Plus Panitumumab Followed by 5-FU/LV Plus Panitumumab or Single-agent Panitumumab as Maintenance Therapy in Patients With RAS Wild-type, Metastatic Colorectal Cancer: the VALENTINO Study | Unknown | Unknown | NCT02476045"
"Teva Pharmaceuticals, Inc.",LAPATINIB,Lapatinib,Y,2023-11-30,Kinase Inhibitor,HER2 | ALK | MET | RET | ATM | ATR | HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR,Kinase Inhibitor,patients with advanced or metastatic breast cancer whose tumor | patients with advanced or metastatic breast cancer whose tumor | adult patients with advanced or metastatic gastric cancer | positive metastatic breast cancer | positive metastatic breast cancer | positive metastatic | locally advanced or metastatic breast cancer | locally advanced or metastatic breast cancer | capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumor | capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumor | capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumor,Lapatinib in Endocrine-Resistant Metastatic Breast Cancer | Unknown | Terminated | NCT00225758 || A Phase II Neo-Adjuvant Study of Letrozole in Combination With Lapatinib in Post -Menopausal Patients With HER2-Positive and Hormone Receptor-Positive Operable Breast Cancer | Unknown | Terminated | NCT00499681
"ENDO USA, Inc.",EVEROLIMUS,Everolimus,Y,2024-07-12,Vaccine,THE | OF | OF | TROUGH | CYTOCHROME,Kinase Inhibitor,patients with functional carcinoid tumor | negative breast cancer | negative breast cancer | postmenopausal women with advanced | adult patients with progressive neuroendocrine tumor | in adult patients with unresectable locally advanced or metastatic disease | locally advanced or metastatic breast cancer | or lung carcinoma | adult patients with advanced | preexisting invasive fungal infection | the treatment of patients with functional carcinoid tumor | the treatment of postmenopausal women with advanced | the treatment of adult patients with progressive neuroendocrine tumor | the treatment of adult patients with advanced endometrial carcinoma | for the treatment of postmenopausal women with advanced | for the treatment of adult patients with progressive neuroendocrine tumor | for the treatment of adult patients with advanced endometrial carcinoma | prophylaxis of allograft rejection in adult patients receiving a liver transplant | pediatric patients aged 1 year,"A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Patients With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer | Unknown | Recruiting | NCT05306340 || An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants With Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1/L1 and VEGF-Targeted Therapies | Unknown | Recruiting | NCT04195750 || A Phase I/II Study of LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy | Unknown | Unknown | NCT02985125 || RANDOMIZED TRIAL OF ZOTAROLIMUS- AND EVEROLIMUS-ELUTING STENTS REGARDING STENT COVERAGE ASSESSED BY OCT | Unknown | Unknown | NCT01230723 || A Phase 2 Study of Dasatinib in Combination With Everolimus for Children With Gliomas Harboring PDGFR Alterations | Phase 2 | Terminated | NCT03352427 || Phase II Study of Everolimus Beyond Progression in Postmenopausal Women With Advanced, Hormone Receptor Positive Breast Cancer | Unknown | Terminated | NCT02269670 || EverolimuS-ElUtinG BioresorbAble VasculaR Scaffolds vErsus EVerolimus-Eluting Stents in Patients With Diabetes Mellitus | Unknown | Terminated | NCT02632292 || Optical Coherence Tomography Assessment of Intimal Tissue and Malapposition: A Randomized Comparison of the Biolimus A9-eluting and Everolimus-eluting Coronary Stents | Unknown | Unknown | NCT01137019 || Evaluation of the Early Conversion From a Calcineurin Inhibitor-based Immunosuppressive Regimen to Everolimus in de Novo Renal Transplant Recipients, a Multicenter Experience | Unknown | Terminated | NCT01609673 || An Open, Randomized Phase III Study of Everolimus With Investigator's Choice of Chemotherapy Versus Chemotherapy in The First-Line Treatment of Luminal Androgen Receptor (LAR) Subtype With PI3K/AKT/mTOR Pathway Mutation of Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer (BCTOP-T-M03) | Unknown | Recruiting | NCT05954442 || Percutaneous Treatment of Very LONG Native Coronary Lesions With Drug-Eluting Stent-VI: Everolimus-eluting Versus Zotarolimus-Eluting Stents | Unknown | Terminated | NCT01489761 || PNOC021: A Phase I Trial Evaluating the Combination of Trametinib and Everolimus in Pediatric and Young Adult Patients With Recurrent Low-Grade Gliomas and High Grade Gliomas | Unknown | Recruiting | NCT04485559"
"Fresenius Kabi USA, LLC",TEMSIROLIMUS,Temsirolimus,Y,2020-03-30,Vaccine,ALK | MET | RET | ATM | MYC | IFN-Α,Kinase Inhibitor,adult patients with advanced renal cell carcinoma | the treatment of advanced renal cell carcinoma | the treatment of advanced testicular cancer | for the treatment of advanced renal cell carcinoma | for the treatment of advanced testicular cancer | for the treatment of advanced renal cell carcinoma | for the treatment of advanced testicular cancer,
Gland Pharma Limited,TEMSIROLIMUS INJECTION,Temsirolimus,Y,2022-10-07,Vaccine,ALK | MET | RET | ATM | MYC | IFN-Α | ALK | MET | RET | ATM | MYC | IFN-Α,Kinase Inhibitor,adult patients with advanced renal cell carcinoma | the treatment of advanced renal cell carcinoma | the treatment of advanced testicular cancer | for the treatment of advanced renal cell carcinoma | for the treatment of advanced testicular cancer | adult patients with advanced renal cell carcinoma | the treatment of advanced renal cell carcinoma | the treatment of advanced testicular cancer | for the treatment of advanced renal cell carcinoma | for the treatment of advanced testicular cancer,
